151
|
Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med 2018; 65:70-99. [PMID: 30056242 DOI: 10.1016/j.mam.2018.07.001] [Citation(s) in RCA: 484] [Impact Index Per Article: 80.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2018] [Accepted: 07/23/2018] [Indexed: 12/13/2022]
Abstract
Cardiac fibrosis is a common pathophysiologic companion of most myocardial diseases, and is associated with systolic and diastolic dysfunction, arrhythmogenesis, and adverse outcome. Because the adult mammalian heart has negligible regenerative capacity, death of a large number of cardiomyocytes results in reparative fibrosis, a process that is critical for preservation of the structural integrity of the infarcted ventricle. On the other hand, pathophysiologic stimuli, such as pressure overload, volume overload, metabolic dysfunction, and aging may cause interstitial and perivascular fibrosis in the absence of infarction. Activated myofibroblasts are the main effector cells in cardiac fibrosis; their expansion following myocardial injury is primarily driven through activation of resident interstitial cell populations. Several other cell types, including cardiomyocytes, endothelial cells, pericytes, macrophages, lymphocytes and mast cells may contribute to the fibrotic process, by producing proteases that participate in matrix metabolism, by secreting fibrogenic mediators and matricellular proteins, or by exerting contact-dependent actions on fibroblast phenotype. The mechanisms of induction of fibrogenic signals are dependent on the type of primary myocardial injury. Activation of neurohumoral pathways stimulates fibroblasts both directly, and through effects on immune cell populations. Cytokines and growth factors, such as Tumor Necrosis Factor-α, Interleukin (IL)-1, IL-10, chemokines, members of the Transforming Growth Factor-β family, IL-11, and Platelet-Derived Growth Factors are secreted in the cardiac interstitium and play distinct roles in activating specific aspects of the fibrotic response. Secreted fibrogenic mediators and matricellular proteins bind to cell surface receptors in fibroblasts, such as cytokine receptors, integrins, syndecans and CD44, and transduce intracellular signaling cascades that regulate genes involved in synthesis, processing and metabolism of the extracellular matrix. Endogenous pathways involved in negative regulation of fibrosis are critical for cardiac repair and may protect the myocardium from excessive fibrogenic responses. Due to the reparative nature of many forms of cardiac fibrosis, targeting fibrotic remodeling following myocardial injury poses major challenges. Development of effective therapies will require careful dissection of the cell biological mechanisms, study of the functional consequences of fibrotic changes on the myocardium, and identification of heart failure patient subsets with overactive fibrotic responses.
Collapse
Affiliation(s)
- Nikolaos G Frangogiannis
- The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, 1300 Morris Park Avenue, Forchheimer G46B, Bronx, NY, 10461, USA.
| |
Collapse
|
152
|
Ayoub KF, Pothineni NVK, Rutland J, Ding Z, Mehta JL. Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. Cardiovasc Drugs Ther 2018; 31:593-608. [PMID: 28956198 DOI: 10.1007/s10557-017-6752-z] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
PURPOSE Heart failure (HF) remains a major cause of morbidity and mortality worldwide. Although various therapies developed over the last two decades have shown improved long term outcomes in patients with established HF, there has been little progress in preventing the adverse cardiac remodeling that initiates HF. To fill the gap in treatment, current research efforts are focused on understanding novel mechanisms and signaling pathways. Immune activation, inflammation, oxidative stress, alterations in mitochondrial bioenergetics, and autophagy have been postulated as important pathophysiological events in this process. An improved understanding of these complex processes could facilitate a therapeutic shift toward molecular targets that can potentially alter the course of HF. METHODS In this review, we address the role of immunity, inflammation, and oxidative stress as well as other novel emerging concepts in the pathophysiology of HF that may have therapeutic implications. CONCLUSION Based on the experimental and clinical studies presented here, we anticipate that a better understanding of the pathophysiology of HF will open the door for new therapeutic targets. A one-size-fits-all approach may not be appropriate for all patients with HF, and further clinical trials utilizing molecular targeting in HF may result in improved outcomes.
Collapse
Affiliation(s)
- Karam F Ayoub
- Division of Cardiology, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Naga Venkata K Pothineni
- Division of Cardiology, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Joshua Rutland
- Division of Cardiology, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Zufeng Ding
- Division of Cardiology, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Jawahar L Mehta
- Division of Cardiology, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA. .,Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham Street, #532, Little Rock, AR, 72205, USA.
| |
Collapse
|
153
|
Emmerson A, Trevelin SC, Mongue-Din H, Becker PD, Ortiz C, Smyth LA, Peng Q, Elgueta R, Sawyer G, Ivetic A, Lechler RI, Lombardi G, Shah AM. Nox2 in regulatory T cells promotes angiotensin II-induced cardiovascular remodeling. J Clin Invest 2018; 128:3088-3101. [PMID: 29688896 PMCID: PMC6025997 DOI: 10.1172/jci97490] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Accepted: 04/17/2018] [Indexed: 12/29/2022] Open
Abstract
The superoxide-generating enzyme Nox2 contributes to hypertension and cardiovascular remodeling triggered by activation of the renin-angiotensin system. Multiple Nox2-expressing cells are implicated in angiotensin II-induced (Ang II-induced) pathophysiology, but the importance of Nox2 in leukocyte subsets is poorly understood. Here, we investigated the role of Nox2 in T cells, particularly Tregs. Mice globally deficient in Nox2 displayed increased numbers of Tregs in the heart at baseline, whereas Ang II-induced effector T cell (Teff) infiltration was inhibited. To investigate the role of Treg Nox2, we generated a mouse line with CD4-targeted Nox2 deficiency (Nox2fl/flCD4Cre+). These animals showed inhibition of Ang II-induced hypertension and cardiac remodeling related to increased tissue-resident Tregs and reduction in infiltrating Teffs, including Th17 cells. The protection in Nox2fl/flCD4Cre+ mice was reversed by anti-CD25 antibody depletion of Tregs. Mechanistically, Nox2-/y Tregs showed higher in vitro suppression of Teff proliferation than WT Tregs, increased nuclear levels of FoxP3 and NF-κB, and enhanced transcription of CD25, CD39, and CD73. Adoptive transfer of Tregs confirmed that Nox2-deficient cells had greater inhibitory effects on Ang II-induced heart remodeling than WT cells. These results identify a previously unrecognized role of Nox2 in modulating suppression of Tregs, which acts to enhance hypertension and cardiac remodeling.
Collapse
Affiliation(s)
- Amber Emmerson
- King’s College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom
| | - Silvia Cellone Trevelin
- King’s College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom
| | - Heloise Mongue-Din
- King’s College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom
| | - Pablo D. Becker
- King’s College London, Medical Research Council Centre for Transplantation, School of Immunology and Microbial Sciences, London, United Kingdom
| | - Carla Ortiz
- King’s College London, Medical Research Council Centre for Transplantation, School of Immunology and Microbial Sciences, London, United Kingdom
| | - Lesley A. Smyth
- King’s College London, Medical Research Council Centre for Transplantation, School of Immunology and Microbial Sciences, London, United Kingdom
| | - Qi Peng
- King’s College London, Medical Research Council Centre for Transplantation, School of Immunology and Microbial Sciences, London, United Kingdom
| | - Raul Elgueta
- King’s College London, Medical Research Council Centre for Transplantation, School of Immunology and Microbial Sciences, London, United Kingdom
| | - Greta Sawyer
- King’s College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom
| | - Aleksandar Ivetic
- King’s College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom
| | - Robert I. Lechler
- King’s College London, Medical Research Council Centre for Transplantation, School of Immunology and Microbial Sciences, London, United Kingdom
| | - Giovanna Lombardi
- King’s College London, Medical Research Council Centre for Transplantation, School of Immunology and Microbial Sciences, London, United Kingdom
| | - Ajay M. Shah
- King’s College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, United Kingdom
| |
Collapse
|
154
|
Willeford A, Suetomi T, Nickle A, Hoffman HM, Miyamoto S, Heller Brown J. CaMKIIδ-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis. JCI Insight 2018; 3:97054. [PMID: 29925681 DOI: 10.1172/jci.insight.97054] [Citation(s) in RCA: 78] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2017] [Accepted: 05/14/2018] [Indexed: 01/08/2023] Open
Abstract
Inflammation accompanies heart failure and is a mediator of cardiac fibrosis. CaMKIIδ plays an essential role in adverse remodeling and decompensation to heart failure. We postulated that inflammation is the mechanism by which CaMKIIδ contributes to adverse remodeling in response to nonischemic interventions. We demonstrate that deletion of CaMKIIδ in the cardiomyocyte (CKO) significantly attenuates activation of NF-κB, expression of inflammatory chemokines and cytokines, and macrophage accumulation induced by angiotensin II (Ang II) infusion. The inflammasome was activated by Ang II, and this response was also diminished in CKO mice. These events occurred prior to any evidence of Ang II-induced cell death. In addition, CaMKII-dependent inflammatory gene expression and inflammasome priming were observed as early as the third hour of infusion, a time point at which macrophage recruitment was not evident. Inhibition of either the inflammasome or monocyte chemoattractant protein 1 (MCP1) signaling attenuated macrophage accumulation, and these interventions, like cardiomyocyte CaMKIIδ deletion, diminished the fibrotic response to Ang II. Thus, activation of CaMKIIδ in the cardiomyocyte represents what we believe to be a novel mechanism for initiating inflammasome activation and an inflammatory gene program that leads to macrophage recruitment and ultimately to development of fibrosis.
Collapse
Affiliation(s)
| | | | | | - Hal M Hoffman
- Department of Medicine, and.,Department of Pediatrics, UCSD, La Jolla, California, USA
| | | | | |
Collapse
|
155
|
Sun XQ, Abbate A, Bogaard HJ. Role of cardiac inflammation in right ventricular failure. Cardiovasc Res 2018; 113:1441-1452. [PMID: 28957536 DOI: 10.1093/cvr/cvx159] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 08/09/2017] [Indexed: 12/18/2022] Open
Abstract
Right ventricular failure (RVF) is the main determinant of mortality in patients with pulmonary arterial hypertension (PAH). Although the exact pathophysiology underlying RVF remains unclear, inflammation may play an important role, as it does in left heart failure. Perivascular pulmonary artery and systemic inflammation is relatively well studied and known to contribute to the initiation and maintenance of the pulmonary vascular insult in PAH. However, less attention has been paid to the role of cardiac inflammation in RVF and PAH. Consistent with many other types of heart failure, cardiac inflammation, triggered by systemic and local stressors, has been shown in RVF patients as well as in RVF animal models. RV inflammation likely contributes to impaired RV contractility, maladaptive remodelling and a vicious circle between RV and pulmonary vascular injury. Although the potential to improve RV function through anti-inflammatory therapy has not been tested, this approach has been applied clinically in left ventricular failure patients, with variable success. Because inflammation plays a dual role in the development of both pulmonary vascular pathology and RVF, anti-inflammatory therapies may have a potential double benefit in patients with PAH and associated RVF.
Collapse
Affiliation(s)
- Xiao-Qing Sun
- Department of Pulmonology, VU University Medical Center/Institute for Cardiovascular Research, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
| | - Antonio Abbate
- Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - Harm-Jan Bogaard
- Department of Pulmonology, VU University Medical Center/Institute for Cardiovascular Research, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
| |
Collapse
|
156
|
Frangogiannis NG. Fibroblasts and the extracellular matrix in right ventricular disease. Cardiovasc Res 2018; 113:1453-1464. [PMID: 28957531 DOI: 10.1093/cvr/cvx146] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 08/01/2017] [Indexed: 12/17/2022] Open
Abstract
Right ventricular failure predicts adverse outcome in patients with pulmonary hypertension (PH), and in subjects with left ventricular heart failure and is associated with interstitial fibrosis. This review manuscript discusses the cellular effectors and molecular mechanisms implicated in right ventricular fibrosis. The right ventricular interstitium contains vascular cells, fibroblasts, and immune cells, enmeshed in a collagen-based matrix. Right ventricular pressure overload in PH is associated with the expansion of the fibroblast population, myofibroblast activation, and secretion of extracellular matrix proteins. Mechanosensitive transduction of adrenergic signalling and stimulation of the renin-angiotensin-aldosterone cascade trigger the activation of right ventricular fibroblasts. Inflammatory cytokines and chemokines may contribute to expansion and activation of macrophages that may serve as a source of fibrogenic growth factors, such as transforming growth factor (TGF)-β. Endothelin-1, TGF-βs, and matricellular proteins co-operate to activate cardiac myofibroblasts, and promote synthesis of matrix proteins. In comparison with the left ventricle, the RV tolerates well volume overload and ischemia; whether the right ventricular interstitial cells and matrix are implicated in these favourable responses remains unknown. Expansion of fibroblasts and extracellular matrix protein deposition are prominent features of arrhythmogenic right ventricular cardiomyopathies and may be implicated in the pathogenesis of arrhythmic events. Prevailing conceptual paradigms on right ventricular remodelling are based on extrapolation of findings in models of left ventricular injury. Considering the unique embryologic, morphological, and physiologic properties of the RV and the clinical significance of right ventricular failure, there is a need further to dissect RV-specific mechanisms of fibrosis and interstitial remodelling.
Collapse
Affiliation(s)
- Nikolaos G Frangogiannis
- Department of Medicine (Cardiology), The Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Forchheimer G46B Bronx, 10461 NY, USA
| |
Collapse
|
157
|
Sydykov A, Mamazhakypov A, Petrovic A, Kosanovic D, Sarybaev AS, Weissmann N, Ghofrani HA, Schermuly RT. Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. Front Physiol 2018; 9:609. [PMID: 29875701 PMCID: PMC5974151 DOI: 10.3389/fphys.2018.00609] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 05/04/2018] [Indexed: 01/07/2023] Open
Abstract
Adverse right ventricular (RV) remodeling leads to ventricular dysfunction and failure that represents an important determinant of outcome in patients with pulmonary hypertension (PH). Recent evidence indicates that inflammatory activation contributes to the pathogenesis of adverse RV remodeling and dysfunction. It has been shown that accumulation of inflammatory cells such as macrophages and mast cells in the right ventricle is associated with maladaptive RV remodeling. In addition, inhibition of inflammation in animal models of RV failure ameliorated RV structural and functional impairment. Furthermore, a number of circulating inflammatory mediators have been demonstrated to be associated with RV performance. This work reviews the role of inflammation in RV remodeling and dysfunction and discusses anti-inflammatory strategies that may attenuate adverse structural alterations while promoting improvement of RV function.
Collapse
Affiliation(s)
- Akylbek Sydykov
- Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Justus Liebig University of Giessen, Giessen, Germany.,Department of Mountain and Sleep Medicine and Pulmonary Hypertension, National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
| | - Argen Mamazhakypov
- Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Justus Liebig University of Giessen, Giessen, Germany
| | - Aleksandar Petrovic
- Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Justus Liebig University of Giessen, Giessen, Germany
| | - Djuro Kosanovic
- Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Justus Liebig University of Giessen, Giessen, Germany
| | - Akpay S Sarybaev
- Department of Mountain and Sleep Medicine and Pulmonary Hypertension, National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
| | - Norbert Weissmann
- Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Justus Liebig University of Giessen, Giessen, Germany
| | - Hossein A Ghofrani
- Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Justus Liebig University of Giessen, Giessen, Germany
| | - Ralph T Schermuly
- Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Justus Liebig University of Giessen, Giessen, Germany
| |
Collapse
|
158
|
Abdullah CS, Jin Z. Targeted deletion of T‐cell S1P receptor 1 ameliorates cardiac fibrosis in streptozotocin‐induced diabetic mice. FASEB J 2018; 32:5426-5435. [DOI: 10.1096/fj.201800231r] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Chowdhury S. Abdullah
- Department of Pharmaceutical SciencesCollege of Pharmacy, South Dakota State University Brookings South Dakota USA
| | - Zhu‐Qiu Jin
- Department of Pharmaceutical and Biomedical SciencesCollege of Pharmacy, California Northstate University Elk Grove California USA
- Department of PathologyLouisiana State University Health Sciences CenterShreveport LA USA
| |
Collapse
|
159
|
Abstract
T-cell infiltration and the subsequent increased intracardial chronic inflammation play crucial roles in the development of cardiac hypertrophy and heart failure (HF). A77 1726, the active metabolite of leflunomide, has been reported to have powerful anti-inflammatory and T cell-inhibiting properties. However, the effect of A77 1726 on cardiac hypertrophy remains completely unknown. Herein, we found that A77 1726 treatment attenuated pressure overload or angiotensin II (Ang II)-induced cardiac hypertrophy in vivo, as well as agonist-induced hypertrophic response of cardiomyocytes in vitro In addition, we showed that A77 1726 administration prevented induction of cardiac fibrosis by inhibiting cardiac fibroblast (CF) transformation into myofibroblast. Surprisingly, we found that the protective effect of A77 1726 was not dependent on its T lymphocyte-inhibiting property. A77 1726 suppressed the activation of protein kinase B (AKT) signaling pathway, and overexpression of constitutively active AKT completely abolished A77 1726-mediated cardioprotective effects in vivo and in vitro Pretreatment with siRNA targetting Fyn (si Fyn) blunted the protective effect elicited by A77 1726 in vitro More importantly, A77 1726 was capable of blocking pre-established cardiac hypertrophy in mice. In conclusion, A77 1726 attenuated cardiac hypertrophy and cardiac fibrosis via inhibiting FYN/AKT signaling pathway.
Collapse
|
160
|
Moro-García MA, López-Iglesias F, Marcos-Fernández R, Bueno-García E, Díaz-Molina B, Lambert JL, Suárez-García FM, Morís de la Tassa C, Alonso-Arias R. More intensive CMV-infection in chronic heart failure patients contributes to higher T-lymphocyte differentiation degree. Clin Immunol 2018; 192:20-29. [PMID: 29608971 DOI: 10.1016/j.clim.2018.03.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 02/08/2018] [Accepted: 03/27/2018] [Indexed: 01/10/2023]
Abstract
Immunosenescence in chronic heart failure (CHF) is characterized by a high frequency of differentiated T-lymphocytes, contributing to an inflammatory status and a deficient ability to generate immunocompetent responses. CMV is the best known inducer of T-lymphocyte differentiation, and is associated with the phenomenon of immunosenescence. In this study, we included 58 elderly chronic heart failure patients (ECHF), 60 healthy elderly controls (HEC), 40 young chronic heart failure patients (YCHF) and 40 healthy young controls (HYC). High differentiation of CD8+ T-lymphocytes was found in CMV-seropositive patients; however, the differentiation of CD4+ T-lymphocytes was increased in CMV-seropositive but also in CHF patients. Anti-CMV antibody titers showed positive correlation with more differentiated CD4+ and CD8+ subsets and inverse correlation with CD4/CD8 ratio. Immunosenescence found in CHF patients is mainly due to the dynamics of CMV-infection, since the differentiation of T-lymphocyte subsets is related not only to CMV-infection, but also to anti-CMV antibody titers.
Collapse
Affiliation(s)
| | - Fernando López-Iglesias
- Sección de Hemodinámica y Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | - Eva Bueno-García
- Immunology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Beatriz Díaz-Molina
- Sección de Hemodinámica y Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - José Luis Lambert
- Sección de Hemodinámica y Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | - Cesar Morís de la Tassa
- Sección de Hemodinámica y Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Rebeca Alonso-Arias
- Immunology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
| |
Collapse
|
161
|
Russell‐Hallinan A, Watson CJ, Baugh JA. Epigenetics of Aberrant Cardiac Wound Healing. Compr Physiol 2018; 8:451-491. [DOI: 10.1002/cphy.c170029] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
162
|
Salvador AM, Moss ME, Aronovitz M, Mueller KB, Blanton RM, Jaffe IZ, Alcaide P. Endothelial mineralocorticoid receptor contributes to systolic dysfunction induced by pressure overload without modulating cardiac hypertrophy or inflammation. Physiol Rep 2018. [PMID: 28637706 PMCID: PMC5492203 DOI: 10.14814/phy2.13313] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Heart Failure (HF) is associated with increased circulating levels of aldosterone and systemic inflammation. Mineralocorticoid receptor (MR) antagonists block aldosterone action and decrease mortality in patients with congestive HF. However, the molecular mechanisms underlying the therapeutic benefits of MR antagonists remain unclear. MR is expressed in all cell types in the heart, including the endothelial cells (EC), in which aldosterone induces the expression of intercellular adhesion molecule 1 (ICAM‐1). Recently, we reported that ICAM‐1 regulates cardiac inflammation and cardiac function in mice subjected to transverse aortic constriction (TAC). Whether MR specifically in endothelial cells (EC) contributes to the several mechanisms of pathological cardiac remodeling and cardiac dysfunction remains unclear. Basal cardiac function and LV dimensions were comparable in mice with MR selectively deleted from ECs (EC‐MR−/−) and wild‐type littermate controls (EC‐MR+/+). MR was specifically deleted in heart EC, and in EC‐containing tissues, but not in leukocytes of TAC EC‐MR−/− mice. While EC‐MR−/−TAC mice showed preserved systolic function and some alterations in the expression of fetal genes, the proinflammatory cytokine TNFα and the endothelin receptors in the LV as compared to EC‐MR+/+TAC mice, no difference was observed between both TAC groups in overall cardiac hypertrophy, ICAM‐1 LV expression and leukocyte infiltration, cardiac fibrosis or capillary rarefaction, all hallmarks of pathological cardiac remodeling. Our data indicate that EC‐MR contributes to the transition of cardiac hypertrophy to systolic dysfunction independently of other maladaptive changes induced by LV pressure overload.
Collapse
Affiliation(s)
- Ane M Salvador
- Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, Massachusetts.,Centro de Investigaciόn Biomédica, Universidad de Granada, Spain
| | - M Elizabeth Moss
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts.,Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts
| | - Mark Aronovitz
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts
| | - Kathleen B Mueller
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts.,Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts
| | - Robert M Blanton
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts
| | - Iris Z Jaffe
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts
| | - Pilar Alcaide
- Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, Massachusetts .,Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts
| |
Collapse
|
163
|
Abstract
Previous studies have suggested the involvement of CD4 + T lymphocytes in cardiac remodelling. T-bet can direct Th1 lineage commitment. This study aimed to investigate the functional significance of T-bet in cardiac remodelling induced by pressure overload using T-bet global knockout rats. Increased T-bet levels were observed in rodent and human hypertrophied hearts. T-bet deficiency resulted in a less severe hypertrophic phenotype in rats. CD4 + T-lymphocyte reconstitution in T-bet-/- rats resulted in aggravated cardiac remodelling. T-cell homing molecule expression and cytokine secretion were altered in T-bet-deficient rat hearts. Administration of exogenous interferon-γ (IFN-γ) offset T-bet deficiency-mediated cardioprotection. Cardiomyocytes cultured in T-bet-/- CD4 + T-cell-conditioned media showed a reduced hypertrophic response after hypertrophic stimuli, which was abolished by an IFN-γ-neutralizing antibody. Taken together, our findings show that T-bet deficiency attenuates pressure overload-induced cardiac remodelling in rats. Specifically, targeting T-bet in T cells may be of great importance for the treatment of pathological cardiac remodelling and heart failure.
Collapse
|
164
|
Alvarez P, Briasoulis A. Immune Modulation in Heart Failure: the Promise of Novel Biologics. CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE 2018. [DOI: 10.1007/s11936-018-0617-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
165
|
Patel B, Bansal SS, Ismahil MA, Hamid T, Rokosh G, Mack M, Prabhu SD. CCR2 + Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload. ACTA ACUST UNITED AC 2018; 3:230-244. [PMID: 30062209 PMCID: PMC6059350 DOI: 10.1016/j.jacbts.2017.12.006] [Citation(s) in RCA: 169] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Revised: 10/11/2017] [Accepted: 12/19/2017] [Indexed: 12/24/2022]
Abstract
Hypothesis: CCR2+ monocyte-derived cardiac macrophages are required for adverse LV remodeling, cardiac T-cell expansion, and the transition to HF following pressure overload. The imposition of pressure overload via TAC resulted in the early up-regulation of CCL2, CCL7, and CCL12 chemokines in the LV, increased Ly6ChiCCR2+ monocytes in the blood, and augmented CCR2+ infiltrating macrophages in the heart. Specific and circumscribed inhibition of CCR2+ monocytes and macrophages early during pressure overload reduced pathological hypertrophy, fibrosis, and systolic dysfunction during the late phase of pressure overload. The early expansion of CCR2+ macrophages after pressure overload was required for long-term cardiac T-cell expansion. CCR2+ monocytes/macrophages may represent key targets for immunomodulation to delay or prevent HF in pressure-overload states.
Although chronic inflammation is a central feature of heart failure (HF), the immune cell profiles differ with different underlying causes. This suggests that for immunomodulatory therapy in HF to be successful, it needs to be tailored to the specific etiology. Here, the authors demonstrate that monocyte-derived C-C chemokine receptor 2 (CCR2)+ macrophages infiltrate the heart early during pressure overload in mice, and that blocking this response either pharmacologically or with antibody-mediated CCR2+ monocyte depletion alleviates late pathological left ventricular remodeling and dysfunction, T-cell expansion, and cardiac fibrosis. Hence, suppression of CCR2+ monocytes/macrophages may be an important immunomodulatory therapeutic target to ameliorate pressure-overload HF.
Collapse
Key Words
- APC, antigen presenting cell
- BNP, B-type natriuretic peptide
- CCL, C-C motif chemokine ligand
- CCR2, C-C chemokine receptor 2
- DC, dendritic cell
- EDTA, ethylenediaminetetraacetic acid
- EF, ejection fraction
- HF, heart failure
- ICAM, intercellular adhesion molecule
- IFN, interferon
- IL, interleukin
- LN, lymph node
- LV, left ventricular
- MerTK, c-mer proto-oncogene tyrosine kinase
- PBS, phosphate-buffered saline
- T cells
- TAC, transverse aortic constriction
- TGF, transforming growth factor
- TNF, tumor necrosis factor
- VCAM, vascular cell adhesion molecule
- cardiac remodeling
- heart failure
- i.p., intraperitoneally
- inflammation
- macrophages
Collapse
Affiliation(s)
- Bindiya Patel
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Shyam S Bansal
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Mohamed Ameen Ismahil
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Tariq Hamid
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Gregg Rokosh
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Matthias Mack
- Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany
| | - Sumanth D Prabhu
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama.,Medical Service, Birmingham VAMC, Birmingham, Alabama
| |
Collapse
|
166
|
Martini E, Stirparo GG, Kallikourdis M. Immunotherapy for cardiovascular disease. J Leukoc Biol 2017; 103:493-500. [PMID: 29345361 DOI: 10.1002/jlb.5mr0717-306r] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 11/16/2017] [Accepted: 11/24/2017] [Indexed: 12/11/2022] Open
Abstract
Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.
Collapse
Affiliation(s)
- Elisa Martini
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, Milan, Italy
| | - Giuliano Giuseppe Stirparo
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, Milan, Italy
| | - Marinos Kallikourdis
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, Milan, Italy.,Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, Italy
| |
Collapse
|
167
|
Abstract
PURPOSE OF REVIEW This review focuses on the complex relationship between inflammation and the onset of acute coronary syndrome and heart failure. RECENT FINDINGS In the last few years, two important lines of research brought new and essential information to light in the pathogenesis of acute coronary syndrome: a) the understanding of the immune mediate mechanisms of inflammation in Ischemic Heart Disease (IHD) and b) evidence that the inflammatory mechanisms associated with atherosclerosis and its complications can be modulated by anti-inflammatory molecules. A large amount of data also suggests that inflammation is a major component in the development and exacerbation of heart failure (HF), in a symbiotic relationship. In particular, recent evidence underlies peculiar aspects of the phenomenon: oxidative stress and autophagy; DAMPS and TLR-4 signaling activation; different macrophages lineage and the contribution of NLRP-3 inflammasome; adaptive immune system. A possible explanation that could unify the pathogenic mechanism of these different conditions is the rising evidence that increased bowel permeability may allow translation of gut microbioma product into the circulation. These findings clearly establish the role of inflammation as the great trigger for two of the major cardiovascular causes of death and morbidity. Further studies are needed, to better clarify the issue and to define more targeted approaches to reduce pathological inflammation while preserving the physiological one.
Collapse
Affiliation(s)
- Luigi M Biasucci
- Department of Cardiovascular Science, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168, Rome, Italy.
| | - Giulio La Rosa
- Department of Cardiovascular Science, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168, Rome, Italy
| | - Daniela Pedicino
- Department of Cardiovascular Science, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168, Rome, Italy
| | - Alessia D'Aiello
- Department of Cardiovascular Science, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168, Rome, Italy
| | - Mattia Galli
- Department of Cardiovascular Science, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168, Rome, Italy
| | - Giovanna Liuzzo
- Department of Cardiovascular Science, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168, Rome, Italy
| |
Collapse
|
168
|
Hirose M, Takano H, Hasegawa H, Tadokoro H, Hashimoto N, Takemura G, Kobayashi Y. The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure. J Pharmacol Sci 2017; 135:164-173. [DOI: 10.1016/j.jphs.2017.11.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 11/14/2017] [Accepted: 11/16/2017] [Indexed: 12/13/2022] Open
|
169
|
Gröschel C, Sasse A, Röhrborn C, Monecke S, Didié M, Elsner L, Kruse V, Bunt G, Lichtman AH, Toischer K, Zimmermann WH, Hasenfuß G, Dressel R. T helper cells with specificity for an antigen in cardiomyocytes promote pressure overload-induced progression from hypertrophy to heart failure. Sci Rep 2017; 7:15998. [PMID: 29167489 PMCID: PMC5700082 DOI: 10.1038/s41598-017-16147-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Accepted: 11/08/2017] [Indexed: 12/13/2022] Open
Abstract
We investigated whether CD4+-T cells with specificity for an antigen in cardiomyocytes promote the progression from hypertrophy to heart failure in mice with increased pressure load due to transverse aortic constriction (TAC). OT-II mice expressing a transgenic T cell receptor (TCR) with specificity for ovalbumin (OVA) on CD4+-T cells and cMy-mOVA mice expressing OVA on cardiomyocytes were crossed. The resulting cMy-mOVA-OT-II mice did not display signs of spontaneous autoimmunity despite the fact that their OVA-specific CD4+-T cells were not anergic. After TAC, progression to heart failure was significantly accelerated in cMy-mOVA-OT-II compared to cMy-mOVA mice. No OVA-specific antibodies were induced in response to TAC in cMy-mOVA-OT-II mice, yet more CD3+ T cells infiltrated their myocardium when compared with TAC-operated cMy-mOVA mice. Systemically, the proportion of activated CD4+-T cells with a Th1 and Th17 cytokine profile was increased in cMy-mOVA-OT-II mice after TAC. Thus, T helper cells with specificity for an antigen in cardiomyocytes can directly promote the progression of heart failure in response to pressure overload independently of autoantibodies.
Collapse
Affiliation(s)
- Carina Gröschel
- Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany.,DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany
| | - André Sasse
- Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany
| | - Charlotte Röhrborn
- Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany
| | - Sebastian Monecke
- Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany.,DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany
| | - Michael Didié
- DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany.,Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany.,Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany
| | - Leslie Elsner
- Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany
| | - Vanessa Kruse
- Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany
| | - Gertrude Bunt
- Clinical Optical Microscopy, Department of Neuropathology, University Medical Center Göttingen, Göttingen, Germany
| | - Andrew H Lichtman
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Karl Toischer
- DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany.,Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany
| | - Wolfram-Hubertus Zimmermann
- DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany.,Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany
| | - Gerd Hasenfuß
- DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany.,Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany
| | - Ralf Dressel
- Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany. .,DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany.
| |
Collapse
|
170
|
Lund A, Giil LM, Slettom G, Nygaard O, Heidecke H, Nordrehaug JE. Antibodies to receptors are associated with biomarkers of inflammation and myocardial damage in heart failure. Int J Cardiol 2017; 250:253-259. [PMID: 29046223 DOI: 10.1016/j.ijcard.2017.10.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Revised: 09/03/2017] [Accepted: 10/02/2017] [Indexed: 12/31/2022]
Abstract
INTRODUCTION Naturally occurring antibodies are linked to inflammation, tissue injury and apoptosis, processes also linked to heart failure. Associations between antibodies, inflammation and myocardial damage, have not been elucidated in heart failure. OBJECTIVE We investigated if 25 antibodies to receptors expressed in the cardiovascular system were associated with troponin-T, biomarkers of inflammation and clinical measures of disease severity, in patients with heart failure. METHODS Antibodies in sera from patients (n=191) with ischemic (n=155) or non-ischemic (n=36) heart failure were measured with full-receptor sandwich enzyme-linked immunosorbent assays. All patients underwent coronary angiography with determination of left ventricular ejection fraction (LVEF) and left ventricular end-diastolic pressure (LVEDP). Measured biomarkers included troponin-T, C-reactive protein, erythrocyte sedimentation rate, fibrinogen and neopterin. RESULTS Stabilin-1-antibodies correlated with troponin-T (β 0.23 p=0.008), soluble endoglin-antibodies with erythrocyte sedimentation rate (β 0.19, p=0.007) and fibrinogen (β 0.28, p<0.001). Platelet-derived growth factor subunit β-antibodies were associated with neopterin (β 0.17, p=0.002). All antibodies were correlated (R 0.26 to 0.91) and formed 4 principal components (PCs). Patients with high CRP and high PC2 had higher NYHA class and patients with high troponin-T and high PC1 had lower LVEDP (interactions, all p<0.05). CONCLUSION Antibodies to receptors are correlated and are associated with biomarkers of inflammation and myocardial damage, which further modifies their association with disease severity in heart failure. Their functional activity and immunological function, remain undecided.
Collapse
Affiliation(s)
- Anders Lund
- Department of Clinical Science, University of Bergen, Bergen, Norway.
| | - Lasse Melvaer Giil
- Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway
| | - Grete Slettom
- Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
| | - Ottar Nygaard
- Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
| | | | - Jan Erik Nordrehaug
- Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Cardiology, Stavanger University Hospital, Stavanger, Norway
| |
Collapse
|
171
|
Frati G, Schirone L, Chimenti I, Yee D, Biondi-Zoccai G, Volpe M, Sciarretta S. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc Res 2017; 113:378-388. [PMID: 28395009 DOI: 10.1093/cvr/cvx011] [Citation(s) in RCA: 146] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 01/20/2017] [Indexed: 02/05/2023] Open
Abstract
Heart failure is a highly morbid and mortal clinical condition that represents the last stage of most cardiovascular disorders. Diabetes is strongly associated with an increased incidence of heart failure and directly promotes cardiac hypertrophy, fibrosis, and apoptosis. These changes, in turn, contribute to the development of ventricular dysfunction. The clinical condition associated with the spectrum of cardiac abnormalities induced by diabetes is termed diabetic cardiomyopathy. Myocardial inflammation has recently emerged as a pathophysiological process contributing to cardiac hypertrophy, fibrosis, and dysfunction in cardiac diseases. Myocardial inflammation is also implicated in the development of diabetic cardiomyopathy. Several molecular mechanisms link diabetes to myocardial inflammation. The NF-κB signalling pathway and the renin-angiotensin-aldosterone system are strongly activated in the diabetic heart, thereby promoting myocardial inflammation. Advanced glycation end-products and damage-associated molecular pattern molecules also represent strong triggers for inflammation. The mediators resulting from this inflammatory process modulate specific intracellular signalling mechanisms in cardiac cells that promote the development of diabetic cardiomyopathy. This review article will provide an overview of the signalling molecular mechanisms linking diabetic cardiomyopathy to myocardial inflammation.
Collapse
Affiliation(s)
- Giacomo Frati
- Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 04100 Latina (LT), Italy.,Department of AngioCardioNeurology, IRCCS Neuromed, 86077 Pozzilli (IS), Italy
| | - Leonardo Schirone
- Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 04100 Latina (LT), Italy
| | - Isotta Chimenti
- Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 04100 Latina (LT), Italy
| | - Derek Yee
- Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Giuseppe Biondi-Zoccai
- Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 04100 Latina (LT), Italy.,Department of AngioCardioNeurology, IRCCS Neuromed, 86077 Pozzilli (IS), Italy
| | - Massimo Volpe
- Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 04100 Latina (LT), Italy.,Department of AngioCardioNeurology, IRCCS Neuromed, 86077 Pozzilli (IS), Italy
| | - Sebastiano Sciarretta
- Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 04100 Latina (LT), Italy.,Department of AngioCardioNeurology, IRCCS Neuromed, 86077 Pozzilli (IS), Italy
| |
Collapse
|
172
|
Nevers T, Salvador AM, Velazquez F, Ngwenyama N, Carrillo-Salinas FJ, Aronovitz M, Blanton RM, Alcaide P. Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure. J Exp Med 2017; 214:3311-3329. [PMID: 28970239 PMCID: PMC5679176 DOI: 10.1084/jem.20161791] [Citation(s) in RCA: 134] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Revised: 06/13/2017] [Accepted: 08/21/2017] [Indexed: 12/20/2022] Open
Abstract
Despite emerging data indicating a role for T cells in profibrotic cardiac repair and healing after ischemia, little is known about whether T cells directly impact cardiac fibroblasts (CFBs) to promote cardiac fibrosis (CF) in nonischemic heart failure (HF). Recently, we reported increased T cell infiltration in the fibrotic myocardium of nonischemic HF patients, as well as the protection from CF and HF in TCR-α-/- mice. Here, we report that T cells activated in such a context are mainly IFN-γ+, adhere to CFB, and induce their transition into myofibroblasts. Th1 effector cells selectively drive CF both in vitro and in vivo, whereas adoptive transfer of Th1 cells, opposite to activated IFN-γ-/- Th cells, partially reconstituted CF and HF in TCR-α-/- recipient mice. Mechanistically, Th1 cells use integrin α4 to adhere to and induce TGF-β in CFB in an IFN-γ-dependent manner. Our findings identify a previously unrecognized role for Th1 cells as integrators of perivascular CF and cardiac dysfunction in nonischemic HF.
Collapse
Affiliation(s)
- Tania Nevers
- Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA
| | - Ane M Salvador
- Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA
| | - Francisco Velazquez
- Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA
| | - Njabulo Ngwenyama
- Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA
| | | | - Mark Aronovitz
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA
| | - Robert M Blanton
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA
| | - Pilar Alcaide
- Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA
| |
Collapse
|
173
|
Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail 2017; 19:1379-1389. [DOI: 10.1002/ejhf.942] [Citation(s) in RCA: 115] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2017] [Revised: 05/26/2017] [Accepted: 06/19/2017] [Indexed: 12/15/2022] Open
Affiliation(s)
- Yingying Zhang
- University Hospital, Department of Cardiology and Cardiovascular Medicine; Eberhard Karls University Tuebingen; Tuebingen Germany
- Section for Cardioimmunology; Eberhard Karls University Tuebingen; Tübingen Germany
- Affiliated Hospital of Qingdao University, Department of Cardiology and Cardiovascular Medicine; Qingdao University; Qingdao China
| | - Johann Bauersachs
- Department of Cardiology and Angiology; Hannover Medical School; Hannover Germany
| | - Harald F. Langer
- University Hospital, Department of Cardiology and Cardiovascular Medicine; Eberhard Karls University Tuebingen; Tuebingen Germany
- Section for Cardioimmunology; Eberhard Karls University Tuebingen; Tübingen Germany
| |
Collapse
|
174
|
Eskandari V, Amirzargar AA, Mahmoudi MJ, Rahnemoon Z, Rahmani F, Sadati S, Rahmati Z, Gorzin F, Hedayat M, Rezaei N. Gene expression and levels of IL-6 and TNFα in PBMCs correlate with severity and functional class in patients with chronic heart failure. Ir J Med Sci 2017; 187:359-368. [PMID: 28889349 DOI: 10.1007/s11845-017-1680-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Accepted: 08/31/2017] [Indexed: 11/26/2022]
Abstract
BACKGROUND Evidence shows that proinflammatory cytokines are important determinants of assessment of severity and prognosis of chronic heart failure (CHF). AIMS We investigated whether peripheral expression of the proinflammmatory factors, TNF-α and IL-6 can predict variable of clinical assessment of patients with CHF. METHODS In this report, we used real-time PCR assay to compare relative gene expression of TNFα and IL-6 in PBMC from CHF patients with various heart diseases (n = 42, EF < 45%, NYHA I to IV) and matched healthy control subjects (n = 42).We also determined the TNFα and IL-6 concentrations of cell culture supernatant of PBMCs with ELISA. RESULTS There was a significant negative correlation between gene expression of TNFα and LVEF(r = 0.4, p < 0.05). Patients with CHF had increased gene expression of TNFα and IL-6 in PBMCs (p < 0.05). They also had elevated the supernatant levels of these cytokines in cultured PBMCs (p < 0.001). Levels of TNFα and IL-6 were increased in ischemic heart disease compared to non-ischemic heart disease. There was a positive correlation between TNFα and IL-6 levels in CHF patients and severity of CHF in patients. Levels of these cytokines were higher in patients with NYHA III-IV than in NYHA I-II and normal subjects. CONCLUSIONS Results of this study indicate that peripheral expression of proinflammatory cytokines, TNF-α and IL-6, is important indicators of severity and prognosis in patients with chronic heart disease.
Collapse
Affiliation(s)
- V Eskandari
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - A A Amirzargar
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - M J Mahmoudi
- Department of Cardiology, Amir Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Z Rahnemoon
- Cardiac Heart Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - F Rahmani
- Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | - S Sadati
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Z Rahmati
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - F Gorzin
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - M Hedayat
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Boston, MA, USA
| | - N Rezaei
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
| |
Collapse
|
175
|
Mechanisms contributing to cardiac remodelling. Clin Sci (Lond) 2017; 131:2319-2345. [PMID: 28842527 DOI: 10.1042/cs20171167] [Citation(s) in RCA: 118] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 07/26/2017] [Accepted: 07/31/2017] [Indexed: 12/14/2022]
Abstract
Cardiac remodelling is classified as physiological (in response to growth, exercise and pregnancy) or pathological (in response to inflammation, ischaemia, ischaemia/reperfusion (I/R) injury, biomechanical stress, excess neurohormonal activation and excess afterload). Physiological remodelling of the heart is characterized by a fine-tuned and orchestrated process of beneficial adaptations. Pathological cardiac remodelling is the process of structural and functional changes in the left ventricle (LV) in response to internal or external cardiovascular damage or influence by pathogenic risk factors, and is a precursor of clinical heart failure (HF). Pathological remodelling is associated with fibrosis, inflammation and cellular dysfunction (e.g. abnormal cardiomyocyte/non-cardiomyocyte interactions, oxidative stress, endoplasmic reticulum (ER) stress, autophagy alterations, impairment of metabolism and signalling pathways), leading to HF. This review describes the key molecular and cellular responses involved in pathological cardiac remodelling.
Collapse
|
176
|
Wang JW, Fontes MSC, Wang X, Chong SY, Kessler EL, Zhang YN, de Haan JJ, Arslan F, de Jager SCA, Timmers L, van Veen TAB, Lam CSP, Kleijn DPVD. Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload. Sci Rep 2017; 7:9193. [PMID: 28835616 PMCID: PMC5569043 DOI: 10.1038/s41598-017-09451-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 07/25/2017] [Indexed: 12/29/2022] Open
Abstract
An involement of Toll-like receptor 2 (TLR2) has been established in cardiac dysfunction after acute myocardial infarction; however, its role in chronic pressure overload is unclear. We sought to evaluate the role of TLR2 in cardiac hypertrophy, fibrosis and dysfunction in sustained pressure overload. We induced pressure overload via transverse aortic constriction (TAC) in TLR2−/− and wild type (WT) mice, and followed temporal changes over 8 weeks. Despite similar increases in heart weight, left ventricular (LV) ejection fraction (EF) and diastolic function (mitral E/A ratio) were preserved in TLR2−/− mice but impaired in WT mice following TAC. TAC produced less LV fibrosis in TLR2−/− mice associated with lower mRNA levels of collagen genes (Col1a1 and Col3a1) and lower protein level of TGFbeta1, compared to WT mice. Following TAC, the influx of macrophages and CD3 T cells into LV was similar between TLR2−/− and WT mice, whereas levels of cyto/chemokines were lower in the heart and plasma in TLR2−/− mice. TLR2−/− bone marrow-derived cells protected against LVEF decline and fibrosis following TAC. Our findings show that leukocytic TLR2 deficiency protects against LV dysfunction and fibrosis probably via a reduction in inflammatory signaling in sustained pressure overload.
Collapse
Affiliation(s)
- Jiong-Wei Wang
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Cardiovascular Research Institute (CVRI), National University Heart Centre Singapore (NUHCS) and National University Health System (NUHS), Singapore, Singapore
| | - Magda S C Fontes
- Department of Medical Physiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands.,Laboratory of Experimental Cardiology, Department of Cardiology, Heart Lung Center Leiden, Leiden University Medical Center, Leiden, The Netherlands
| | - Xiaoyuan Wang
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Cardiovascular Research Institute (CVRI), National University Heart Centre Singapore (NUHCS) and National University Health System (NUHS), Singapore, Singapore
| | - Suet Yen Chong
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Cardiovascular Research Institute (CVRI), National University Heart Centre Singapore (NUHCS) and National University Health System (NUHS), Singapore, Singapore
| | - Elise L Kessler
- Department of Medical Physiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands
| | - Ya-Nan Zhang
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Cardiovascular Research Institute (CVRI), National University Heart Centre Singapore (NUHCS) and National University Health System (NUHS), Singapore, Singapore
| | - Judith J de Haan
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Fatih Arslan
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Saskia C A de Jager
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.,Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Leo Timmers
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Toon A B van Veen
- Department of Medical Physiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands
| | - Carolyn S P Lam
- National Heart Centre Singapore, Duke-NUS Graduate Medical School, Singapore, Singapore. .,Cardiology, University Medical Center, Groningen, The Netherlands.
| | - Dominique P V de Kleijn
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. .,Cardiovascular Research Institute (CVRI), National University Heart Centre Singapore (NUHCS) and National University Health System (NUHS), Singapore, Singapore. .,Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands. .,Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. .,Netherlands Heart Institute, Utrecht, The Netherlands.
| |
Collapse
|
177
|
Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, Prabhu SD. Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure. Circ Heart Fail 2017; 10:e003688. [PMID: 28242779 DOI: 10.1161/circheartfailure.116.003688] [Citation(s) in RCA: 199] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Accepted: 01/23/2017] [Indexed: 12/20/2022]
Abstract
BACKGROUND Inappropriately sustained inflammation is a hallmark of chronic ischemic heart failure (HF); however, the pathophysiological role of T lymphocytes is unclear. METHODS AND RESULTS Permanent coronary ligation was performed in adult C57BL/6 mice. When compared with sham-operated mice, mice with HF (8 weeks after ligation) exhibited the following features: (1) significant (P<0.05) expansion of circulating CD3+CD8+ cytotoxic and CD3+CD4+ helper (Th) T lymphocytes, together with increased Th1, Th2, Th17, and regulatory T-cell (Treg) CD4+ subsets; (2) significant expansion of CD8+ and CD4+ T cells in failing myocardium, with increased Th1, Th2, Th17, and Treg CD4+ subsets, marked reduction of the Th1/Th2 ratio, augmentation of the Th17/Treg ratio, and upregulation of Th2 cytokines; and (3) significantly increased Th1, Th2, Th17 cells, and Tregs, in the spleen and mediastinal lymph nodes, with expansion of splenic antigen-experienced effector and memory CD4+ T cells. Antibody-mediated CD4+ T-cell depletion in HF mice (starting 4 weeks after ligation) reduced cardiac infiltration of CD4+ T cells and prevented progressive left ventricular dilatation and hypertrophy, whereas adoptive transfer of splenic CD4+ T cells (and, to a lesser extent, cardiac CD3+ T cells) from donor mice with HF induced long-term left ventricular dysfunction, fibrosis, and hypertrophy in naive recipient mice. CONCLUSIONS CD4+ T lymphocytes are globally expanded and activated in chronic ischemic HF, with Th2 (versus Th1) and Th17 (versus Treg) predominance in failing hearts, and with expansion of memory T cells in the spleen. Cardiac and splenic T cells in HF are primed to induce cardiac injury and remodeling, and retain this memory on adoptive transfer.
Collapse
Affiliation(s)
- Shyam S Bansal
- From the Division of Cardiovascular Disease, Comprehensive Cardiovascular Center, University of Alabama at Birmingham (S.S.B., M.A.I., M.G., B.P., T.H., S.D.P.); and Medical Service, Birmingham Veterans Administration Medical Center, AL (S.S.B., S.D.P.)
| | - Mohamed Ameen Ismahil
- From the Division of Cardiovascular Disease, Comprehensive Cardiovascular Center, University of Alabama at Birmingham (S.S.B., M.A.I., M.G., B.P., T.H., S.D.P.); and Medical Service, Birmingham Veterans Administration Medical Center, AL (S.S.B., S.D.P.)
| | - Mehak Goel
- From the Division of Cardiovascular Disease, Comprehensive Cardiovascular Center, University of Alabama at Birmingham (S.S.B., M.A.I., M.G., B.P., T.H., S.D.P.); and Medical Service, Birmingham Veterans Administration Medical Center, AL (S.S.B., S.D.P.)
| | - Bindiya Patel
- From the Division of Cardiovascular Disease, Comprehensive Cardiovascular Center, University of Alabama at Birmingham (S.S.B., M.A.I., M.G., B.P., T.H., S.D.P.); and Medical Service, Birmingham Veterans Administration Medical Center, AL (S.S.B., S.D.P.)
| | - Tariq Hamid
- From the Division of Cardiovascular Disease, Comprehensive Cardiovascular Center, University of Alabama at Birmingham (S.S.B., M.A.I., M.G., B.P., T.H., S.D.P.); and Medical Service, Birmingham Veterans Administration Medical Center, AL (S.S.B., S.D.P.)
| | - Gregg Rokosh
- From the Division of Cardiovascular Disease, Comprehensive Cardiovascular Center, University of Alabama at Birmingham (S.S.B., M.A.I., M.G., B.P., T.H., S.D.P.); and Medical Service, Birmingham Veterans Administration Medical Center, AL (S.S.B., S.D.P.)
| | - Sumanth D Prabhu
- From the Division of Cardiovascular Disease, Comprehensive Cardiovascular Center, University of Alabama at Birmingham (S.S.B., M.A.I., M.G., B.P., T.H., S.D.P.); and Medical Service, Birmingham Veterans Administration Medical Center, AL (S.S.B., S.D.P.).
| |
Collapse
|
178
|
Li C, Sun XN, Zeng MR, Zheng XJ, Zhang YY, Wan Q, Zhang WC, Shi C, Du LJ, Ai TJ, Liu Y, Liu Y, Du LL, Yi Y, Yu Y, Duan SZ. Mineralocorticoid Receptor Deficiency in T Cells Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction Through Modulating T-Cell Activation. Hypertension 2017; 70:137-147. [PMID: 28559389 DOI: 10.1161/hypertensionaha.117.09070] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Revised: 01/25/2017] [Accepted: 04/28/2017] [Indexed: 12/11/2022]
Abstract
Although antagonists of mineralocorticoid receptor (MR) have been widely used to treat heart failure, the underlying mechanisms are incompletely understood. Recent reports show that T cells play important roles in pathologic cardiac hypertrophy and heart failure. However, it is unclear whether and how MR functions in T cells under these pathologic conditions. We found that MR antagonist suppressed abdominal aortic constriction-induced cardiac hypertrophy and decreased the accumulation and activation of CD4+ and CD8+ T cells in mouse heart. T-cell MR knockout mice manifested suppressed cardiac hypertrophy, fibrosis, and dysfunction compared with littermate control mice after abdominal aortic constriction. T-cell MR knockout mice had less cardiac inflammatory response, which was illustrated by decreased accumulation of myeloid cells and reduced expression of inflammatory cytokines. Less amounts and activation of T cells were observed in the heart of T-cell MR knockout mice after abdominal aortic constriction. In vitro studies showed that both MR antagonism and deficiency repressed activation of T cells, whereas MR overexpression elevated activation of T cells. These results demonstrated that MR blockade in T cells protected against abdominal aortic constriction-induced cardiac hypertrophy and dysfunction. Mechanistically, MR directly regulated T-cell activation and modulated cardiac inflammation. Targeting MR in T cells specifically may be a feasible strategy for more effective treatment of pathologic cardiac hypertrophy and heart failure.
Collapse
Affiliation(s)
- Chao Li
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Xue-Nan Sun
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Meng-Ru Zeng
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Xiao-Jun Zheng
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Yu-Yao Zhang
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Qiangyou Wan
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Wu-Chang Zhang
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Chaoji Shi
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Lin-Juan Du
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Tang-Jun Ai
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Yuan Liu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Yan Liu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Li-Li Du
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Yi Yi
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Ying Yu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Sheng-Zhong Duan
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu).
| |
Collapse
|
179
|
Affiliation(s)
- Gustavo Ramos
- Department of Internal Medicine, University Hospital Halle, Halle, Germany
| | - Stefan Frantz
- Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany
| |
Collapse
|
180
|
Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest 2017; 127:1600-1612. [PMID: 28459429 DOI: 10.1172/jci87491] [Citation(s) in RCA: 326] [Impact Index Per Article: 46.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
The cardiac extracellular matrix (ECM) not only provides mechanical support, but also transduces essential molecular signals in health and disease. Following myocardial infarction, dynamic ECM changes drive inflammation and repair. Early generation of bioactive matrix fragments activates proinflammatory signaling. The formation of a highly plastic provisional matrix facilitates leukocyte infiltration and activates infarct myofibroblasts. Deposition of matricellular proteins modulates growth factor signaling and contributes to the spatial and temporal regulation of the reparative response. Mechanical stress due to pressure and volume overload and metabolic dysfunction also induce profound changes in ECM composition that contribute to the pathogenesis of heart failure. This manuscript reviews the role of the ECM in cardiac repair and remodeling and discusses matrix-based therapies that may attenuate remodeling while promoting repair and regeneration.
Collapse
|
181
|
Wang H, Kwak D, Fassett J, Liu X, Yao W, Weng X, Xu X, Xu Y, Bache RJ, Mueller DL, Chen Y. Role of bone marrow-derived CD11c + dendritic cells in systolic overload-induced left ventricular inflammation, fibrosis and hypertrophy. Basic Res Cardiol 2017; 112:25. [PMID: 28349258 DOI: 10.1007/s00395-017-0615-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Accepted: 03/22/2017] [Indexed: 11/30/2022]
Abstract
Inflammatory responses play an important role in the development of left ventricular (LV) hypertrophy and dysfunction. Recent studies demonstrated that increased T-cell infiltration and T-cell activation contribute to LV hypertrophy and dysfunction. Dendritic cells (DCs) are professional antigen-presenting cells that orchestrate immune responses, especially by modulating T-cell function. In this study, we investigated the role of bone marrow-derived CD11c+ DCs in transverse aortic constriction (TAC)-induced LV fibrosis and hypertrophy in mice. We observed that TAC increased the number of CD11c+ cells and the percentage of CD11c+ MHCII+ (major histocompatibility complex class II molecule positive) DCs in the LV, spleen and peripheral blood in mice. Using bone marrow chimeras and an inducible CD11c+ DC ablation model, we found that depletion of bone marrow-derived CD11c+ DCs significantly attenuated LV fibrosis and hypertrophy in mice exposed to 24 weeks of moderate TAC. CD11c+ DC ablation significantly reduced TAC-induced myocardial inflammation as indicated by reduced myocardial CD45+ cells, CD11b+ cells, CD8+ T cells and activated effector CD8+CD44+ T cells in LV tissues. Moreover, pulsing of autologous DCs with LV homogenates from TAC mice promoted T-cell proliferation. These data indicate that bone marrow-derived CD11c+ DCs play a maladaptive role in hemodynamic overload-induced cardiac inflammation, hypertrophy and fibrosis through the presentation of cardiac self-antigens to T cells.
Collapse
Affiliation(s)
- Huan Wang
- Cardiovascular Division and Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
| | - Dongmin Kwak
- Cardiovascular Division and Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
| | - John Fassett
- Department of Pharmacology and Toxicology, University of Graz, Graz, Austria
| | - Xiaohong Liu
- Shanxi Provincial People's Hospital, Taiyuan, China
| | - Wu Yao
- Cardiovascular Division and Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
| | - Xinyu Weng
- Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China
| | - Xin Xu
- Cardiovascular Division and Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
| | - Yawei Xu
- Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China
| | - Robert J Bache
- Cardiovascular Division and Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
| | - Daniel L Mueller
- Division of Rheumatic and Autoimmune Diseases, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
| | - Yingjie Chen
- Cardiovascular Division and Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, MN, 55455, USA. .,Lillehei Heart Institute, University of Minnesota, Cancer and Cardiovascular Research Building (CCRB), 2231 6th Street SE, 4-135, Minneapolis, MN, 55455, USA.
| |
Collapse
|
182
|
Ramos GC, van den Berg A, Nunes-Silva V, Weirather J, Peters L, Burkard M, Friedrich M, Pinnecker J, Abeßer M, Heinze KG, Schuh K, Beyersdorf N, Kerkau T, Demengeot J, Frantz S, Hofmann U. Myocardial aging as a T-cell-mediated phenomenon. Proc Natl Acad Sci U S A 2017; 114:E2420-E2429. [PMID: 28255084 PMCID: PMC5373357 DOI: 10.1073/pnas.1621047114] [Citation(s) in RCA: 125] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
In recent years, the myocardium has been rediscovered under the lenses of immunology, and lymphocytes have been implicated in the pathogenesis of cardiomyopathies with different etiologies. Aging is an important risk factor for heart diseases, and it also has impact on the immune system. Thus, we sought to determine whether immunological activity would influence myocardial structure and function in elderly mice. Morphological, functional, and molecular analyses revealed that the age-related myocardial impairment occurs in parallel with shifts in the composition of tissue-resident leukocytes and with an accumulation of activated CD4+ Foxp3- (forkhead box P3) IFN-γ+ T cells in the heart-draining lymph nodes. A comprehensive characterization of different aged immune-deficient mouse strains revealed that T cells significantly contribute to age-related myocardial inflammation and functional decline. Upon adoptive cell transfer, the T cells isolated from the mediastinal lymph node (med-LN) of aged animals exhibited increased cardiotropism, compared with cells purified from young donors or from other irrelevant sites. Nevertheless, these cells caused rather mild effects on cardiac functionality, indicating that myocardial aging might stem from a combination of intrinsic and extrinsic (immunological) factors. Taken together, the data herein presented indicate that heart-directed immune responses may spontaneously arise in the elderly, even in the absence of a clear tissue damage or concomitant infection. These observations might shed new light on the emerging role of T cells in myocardial diseases, which primarily affect the elderly population.
Collapse
Affiliation(s)
- Gustavo Campos Ramos
- Department of Internal Medicine III, University Clinic Halle, D-06120 Halle, Germany;
- Comprehensive Heart Failure Center, University Clinic Wuerzburg, D-97078 Wuerzburg, Germany
| | - Anne van den Berg
- Comprehensive Heart Failure Center, University Clinic Wuerzburg, D-97078 Wuerzburg, Germany
| | | | - Johannes Weirather
- Comprehensive Heart Failure Center, University Clinic Wuerzburg, D-97078 Wuerzburg, Germany
| | - Laura Peters
- Comprehensive Heart Failure Center, University Clinic Wuerzburg, D-97078 Wuerzburg, Germany
| | - Matthias Burkard
- Comprehensive Heart Failure Center, University Clinic Wuerzburg, D-97078 Wuerzburg, Germany
| | - Mike Friedrich
- Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, D-97080 Wuerzburg, Germany
| | - Jürgen Pinnecker
- Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, D-97080 Wuerzburg, Germany
| | - Marco Abeßer
- Institute of Physiology I, University of Wuerzburg, D-97070 Wuerzburg, Germany
| | - Katrin G Heinze
- Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, D-97080 Wuerzburg, Germany
| | - Kai Schuh
- Institute of Physiology I, University of Wuerzburg, D-97070 Wuerzburg, Germany
| | - Niklas Beyersdorf
- Institute for Virology and Immunobiology, University of Wuerzburg, D-97078 Wuerzburg, Germany
| | - Thomas Kerkau
- Institute for Virology and Immunobiology, University of Wuerzburg, D-97078 Wuerzburg, Germany
| | | | - Stefan Frantz
- Department of Internal Medicine III, University Clinic Halle, D-06120 Halle, Germany
- Comprehensive Heart Failure Center, University Clinic Wuerzburg, D-97078 Wuerzburg, Germany
| | - Ulrich Hofmann
- Department of Internal Medicine III, University Clinic Halle, D-06120 Halle, Germany
- Comprehensive Heart Failure Center, University Clinic Wuerzburg, D-97078 Wuerzburg, Germany
| |
Collapse
|
183
|
Kallikourdis M, Martini E, Carullo P, Sardi C, Roselli G, Greco CM, Vignali D, Riva F, Ormbostad Berre AM, Stølen TO, Fumero A, Faggian G, Di Pasquale E, Elia L, Rumio C, Catalucci D, Papait R, Condorelli G. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat Commun 2017; 8:14680. [PMID: 28262700 PMCID: PMC5343521 DOI: 10.1038/ncomms14680] [Citation(s) in RCA: 131] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Accepted: 01/23/2017] [Indexed: 02/07/2023] Open
Abstract
Heart failure (HF) is a leading cause of mortality. Inflammation is implicated in HF, yet clinical trials targeting pro-inflammatory cytokines in HF were unsuccessful, possibly due to redundant functions of individual cytokines. Searching for better cardiac inflammation targets, here we link T cells with HF development in a mouse model of pathological cardiac hypertrophy and in human HF patients. T cell costimulation blockade, through FDA-approved rheumatoid arthritis drug abatacept, leads to highly significant delay in progression and decreased severity of cardiac dysfunction in the mouse HF model. The therapeutic effect occurs via inhibition of activation and cardiac infiltration of T cells and macrophages, leading to reduced cardiomyocyte death. Abatacept treatment also induces production of anti-inflammatory cytokine interleukin-10 (IL-10). IL-10-deficient mice are refractive to treatment, while protection could be rescued by transfer of IL-10-sufficient B cells. These results suggest that T cell costimulation blockade might be therapeutically exploited to treat HF. Abatacept is an FDA-approved drug used for treatment of rheumatoid arthritis. Here the authors show that abatacept reduces cardiomyocyte death in a mouse model of heart failure by inhibiting activation and heart infiltration of T cells and macrophages, an effect mediated by IL-10, suggesting a potential therapy for heart failure.
Collapse
Affiliation(s)
- Marinos Kallikourdis
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy.,Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, Rozzano, 20089 Milan, Italy
| | - Elisa Martini
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Pierluigi Carullo
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy.,Institute of Genetic and Biomedical Research (IRGB)-UOS of Milan, National Research Council of Italy, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Claudia Sardi
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Giuliana Roselli
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Carolina M Greco
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Debora Vignali
- Adaptive Immunity Laboratory, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Federica Riva
- Department of Veterinary Medicine (DIMEVET), Università degli Studi di Milano, Via Celoria 10, 20133 Milan, Italy
| | - Anne Marie Ormbostad Berre
- KG Jebsen Centre of Medicine, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Postboks 8905, 7491 Trondheim, Norway
| | - Tomas O Stølen
- KG Jebsen Centre of Medicine, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Postboks 8905, 7491 Trondheim, Norway.,Norwegian Health Association, Oscars gate 36A, 0258 Oslo, Norway
| | - Andrea Fumero
- Cardiac Surgery, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Giuseppe Faggian
- Department of Cardiac Surgery, University of Verona, 37129 Verona, Italy
| | - Elisa Di Pasquale
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy.,Institute of Genetic and Biomedical Research (IRGB)-UOS of Milan, National Research Council of Italy, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Leonardo Elia
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy.,Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
| | - Cristiano Rumio
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Trentacoste 2, 20133 Milan, Italy
| | - Daniele Catalucci
- Institute of Genetic and Biomedical Research (IRGB)-UOS of Milan, National Research Council of Italy, Via Manzoni 56, Rozzano, 20089 Milan, Italy.,Laboratory of Signal Transduction in Cardiac Pathologies, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Roberto Papait
- Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy.,Institute of Genetic and Biomedical Research (IRGB)-UOS of Milan, National Research Council of Italy, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| | - Gianluigi Condorelli
- Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, Rozzano, 20089 Milan, Italy.,Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
| |
Collapse
|
184
|
Laroumanie F, Dale BL, Saleh MA, Madhur MS. Intracellular Staining and Flow Cytometry to Identify Lymphocyte Subsets within Murine Aorta, Kidney and Lymph Nodes in a Model of Hypertension. J Vis Exp 2017:55266. [PMID: 28190037 PMCID: PMC5352305 DOI: 10.3791/55266] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
It is now well known that T lymphocytes play a critical role in the development of several cardiovascular diseases1,2,3,4,5. For example, studies from our group have shown that hypertension is associated with an excessive accumulation of T cells in the vessels and kidney during the development of experimental hypertension6. Once in these tissues, T cells produce several cytokines that affect both vascular and renal function leading to vasoconstriction and sodium and water retention1,2. To fully understand how T cells cause cardiovascular and renal diseases, it is important to be able to identify and quantify the specific T cell subsets present in these tissues. T cell subsets are defined by a combination of surface markers, the cytokines they secrete, and the transcription factors they express. The complexity of the T cell population makes flow cytometry and intracellular staining an invaluable technique to dissect the phenotypes of the lymphocytes present in tissues. Here, we provide a detailed protocol to identify the surface and intracellular markers (cytokines and transcription factors) in T cells isolated from murine kidney, aorta and aortic draining lymph nodes in a model of angiotensin II induced hypertension. The following steps are described in detail: isolation of the tissues, generation of the single cell suspensions, ex vivo stimulation, fixation, permeabilization and staining. In addition, several fundamental principles of flow cytometric analyses including choosing the proper controls and appropriate gating strategies are discussed.
Collapse
Affiliation(s)
- Fanny Laroumanie
- Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center
| | - Bethany L Dale
- Department of Molecular Physiology and Biophysics, Vanderbilt University
| | - Mohamed A Saleh
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University
| | - Meena S Madhur
- Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center;
| |
Collapse
|
185
|
Patel B, Ismahil MA, Hamid T, Bansal SS, Prabhu SD. Mononuclear Phagocytes Are Dispensable for Cardiac Remodeling in Established Pressure-Overload Heart Failure. PLoS One 2017; 12:e0170781. [PMID: 28125666 PMCID: PMC5268479 DOI: 10.1371/journal.pone.0170781] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Accepted: 01/10/2017] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Although cardiac and splenic mononuclear phagocytes (MPs), i.e., monocytes, macrophages and dendritic cells (DCs), are key contributors to cardiac remodeling after myocardial infarction, their role in pressure-overload remodeling is unclear. We tested the hypothesis that these immune cells are required for the progression of remodeling in pressure-overload heart failure (HF), and that MP depletion would ameliorate remodeling. METHODS AND RESULTS C57BL/6 mice were subjected to transverse aortic constriction (TAC) or sham operation, and assessed for alterations in MPs. As compared with sham, TAC mice exhibited expansion of circulating LyC6hi monocytes and pro-inflammatory CD206- cardiac macrophages early (1 w) after pressure-overload, prior to significant hypertrophy and systolic dysfunction, with subsequent resolution during chronic HF. In contrast, classical DCs were expanded in the heart in a biphasic manner, with peaks both early, analogous to macrophages, and late (8 w), during established HF. There was no significant expansion of circulating DCs, or Ly6C+ monocytes and DCs in the spleen. Periodic systemic MP depletion from 2 to 16 w after TAC in macrophage Fas-induced apoptosis (MaFIA) transgenic mice did not alter cardiac remodeling progression, nor did splenectomy in mice with established HF after TAC. Lastly, adoptive transfer of splenocytes from TAC HF mice into naïve recipients did not induce immediate or long-term cardiac dysfunction in recipient mice. CONCLUSIONS Mononuclear phagocytes populations expand in a phasic manner in the heart during pressure-overload. However, they are dispensable for the progression of remodeling and failure once significant hypertrophy is evident and blood monocytosis has normalized.
Collapse
Affiliation(s)
- Bindiya Patel
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Mohamed Ameen Ismahil
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Tariq Hamid
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Shyam S. Bansal
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Sumanth D. Prabhu
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Medical Service, Birmingham VA Medical Center, Birmingham, AL, United States of America
- * E-mail:
| |
Collapse
|
186
|
Zlatanova I, Pinto C, Silvestre JS. Immune Modulation of Cardiac Repair and Regeneration: The Art of Mending Broken Hearts. Front Cardiovasc Med 2016; 3:40. [PMID: 27790620 PMCID: PMC5063859 DOI: 10.3389/fcvm.2016.00040] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Accepted: 09/30/2016] [Indexed: 12/15/2022] Open
Abstract
The accumulation of immune cells is among the earliest responses that manifest in the cardiac tissue after injury. Both innate and adaptive immunity coordinate distinct and mutually non-exclusive events governing cardiac repair, including elimination of the cellular debris, compensatory growth of the remaining cardiac tissue, activation of resident or circulating precursor cells, quantitative and qualitative modifications of the vascular network, and formation of a fibrotic scar. The present review summarizes the mounting evidence suggesting that the inflammatory response also guides the regenerative process following cardiac damage. In particular, recent literature has reinforced the central role of monocytes/macrophages in poising the refreshment of cardiomyocytes in myocardial infarction- or apical resection-induced cardiac insult. Macrophages dictate cardiac myocyte renewal through stimulation of preexisting cardiomyocyte proliferation and/or neovascularization. Nevertheless, substantial efforts are required to identify the nature of these macrophage-derived factors as well as the molecular mechanisms engendered by the distinct subsets of macrophages pertaining in the cardiac tissue. Among the growing inflammatory intermediaries that have been recognized as essential player in heart regeneration, we will focus on the role of interleukin (IL)-6 and IL-13. Finally, it is likely that within the mayhem of the injured cardiac tissue, additional types of inflammatory cells, such as neutrophils, will enter the dance to ignite and refresh the broken heart. However, the protective and detrimental inflammatory pathways have been mainly deciphered in animal models. Future research should be focused on understanding the cellular effectors and molecular signals regulating inflammation in human heart to pave the way for the development of factual therapies targeting the inflammatory compartment in cardiac diseases.
Collapse
Affiliation(s)
- Ivana Zlatanova
- UMRS-970, Paris Centre de Recherche Cardiovasculaire, Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Paris Cité, Université Paris Descartes , Paris , France
| | - Cristina Pinto
- UMRS-970, Paris Centre de Recherche Cardiovasculaire, Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Paris Cité, Université Paris Descartes , Paris , France
| | - Jean-Sébastien Silvestre
- UMRS-970, Paris Centre de Recherche Cardiovasculaire, Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Paris Cité, Université Paris Descartes , Paris , France
| |
Collapse
|
187
|
The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart. J Immunol Res 2016; 2016:4396368. [PMID: 27795961 PMCID: PMC5066021 DOI: 10.1155/2016/4396368] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 08/16/2016] [Accepted: 08/30/2016] [Indexed: 12/13/2022] Open
Abstract
Accumulating evidence reveals involvement of T lymphocytes and adaptive immunity in the chronic inflammation associated with infectious and noninfectious diseases of the heart, including coronary artery disease, Kawasaki disease, myocarditis, dilated cardiomyopathies, Chagas, hypertensive left ventricular (LV) hypertrophy, and nonischemic heart failure. Chemokine CXCL10 is elevated in cardiovascular diseases, along with increased cardiac infiltration of proinflammatory Th1 and cytotoxic T cells. CXCL10 is a chemoattractant for these T cells and polarizing factor for the proinflammatory phenotype. Thus, targeting the CXCL10 receptor CXCR3 is a promising therapeutic approach to treating cardiac inflammation. Due to biased signaling CXCR3 also couples to anti-inflammatory signaling and immunosuppressive regulatory T cell formation when activated by CXCL11. Numbers and functionality of regulatory T cells are reduced in patients with cardiac inflammation, supporting the utility of biased agonists or biologicals to simultaneously block the pro-inflammatory and activate the anti-inflammatory actions of CXCR3. Other immunotherapy strategies to boost regulatory T cell actions include intravenous immunoglobulin (IVIG) therapy, adoptive transfer, immunoadsorption, and low-dose interleukin-2/interleukin-2 antibody complexes. Pharmacological approaches include sphingosine 1-phosphate receptor 1 agonists and vitamin D supplementation. A combined strategy of switching CXCR3 signaling from pro- to anti-inflammatory and improving Treg functionality is predicted to synergistically lessen adverse cardiac remodeling.
Collapse
|
188
|
OX40 regulates pressure overload-induced cardiac hypertrophy and remodelling via CD4+ T-cells. Clin Sci (Lond) 2016; 130:2061-2071. [PMID: 27580926 DOI: 10.1042/cs20160074] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 08/30/2016] [Indexed: 11/17/2022]
Abstract
OX40, which belongs to the tumour necrosis factor (TNF)-receptor family, is a costimulatory receptor that can potentiate T-cell receptor signalling on the surface of T-lymphocytes. The role of OX40 in non-immune systems, particularly the cardiovascular system, has not been defined. In the present study, we observed a noticeable increase in OX40 expression during cardiac remodelling in rodent heart. In the present study, cardiac hypertrophy was induced by aortic banding (AB) in OX40 knockout (KO) mice and wild-type (WT) mice. After 8 weeks, the OX40 KO mice showed significantly attenuated cardiac hypertrophy, fibrosis and inflammation as well as preserved cardiac function compared with the WT mice. Follow-up in vitro studies suggested that CD4+ T-lymphocyte proliferation and pro-inflammatory cytokine release were significantly decreased, whereas anti-inflammatory cytokine release was considerably increased in OX40 KO mice compared with WT mice as assessed by Cell Counting Kit-8 (CCK-8) assay and ELISA. Co-culturing neonatal rat cardiomyocytes with the activated supernatant of CD4+ T-lymphocytes from OX40 KO mice reduced the hypertrophy response. Interestingly, OX40 KO mice with reconstituted CD4+ T-lymphocytes presented deteriorated cardiac remodelling. Collectively, our data indicate that OX40 regulates cardiac remodelling via the modulation of CD4+ T-lymphocytes.
Collapse
|
189
|
Abstract
OBJECTIVE Recent studies have shown that activation of the immune system, inflammatory cell infiltration, and activation of inflammatory mediators play an important role in the development of heart failure. The purpose of this study was to investigate whether cardiac function can be improved by regulating the balance of lymphocyte subsets and cytokines. METHODS Ninety-six patients with chronic heart failure (CHF) who were older than 60 years were randomly divided into two groups: CHF testing group (CHFT) received regular therapy and thymopentin (2 mg thymopentin per day, 15th as a course, three courses in total). CHF control group (CHFC) received regular therapy. Forty-five healthy individuals older than 60 years were used as normal controls. The ejection fraction of left ventricle (LVEF), inner diameter of left ventricular end-diastole (LVEDD), inner diameter of left ventricular end-systole (LVESD), plasma high sensitive C-reactive protein (hsCRP), plasma brain natriuretic peptide (BNP), 6-min walking distance (6MWT), Minnesota Living with Heart Failure Questionnaire (MLHFQ) assessment, lymphocyte subsets, and inflammatory cytokines were tested. RESULTS The levels of LVEF, 6MWT, CD 3+, CD4+T cells, natural killer cells, CD4+/CD8+ and IL-10 in CHFT were increased (p<0.01) compared with CHFC, while BNP, hsCRP, MLHFQ, CD8+, TNF-α, IL-1ß, and TNF-α/IL-10 ratio in CHFT were decreased (p<0.01). LVEDD and LVESD were decreased, even though there was no significant difference between the two CHF groups. CONCLUSION These data suggest that immune modulation therapy improve cardiac function and regulate cytokines and lymphocyte subsets in older patients with CHF.
Collapse
|
190
|
Wang H, Kwak D, Fassett J, Hou L, Xu X, Burbach BJ, Thenappan T, Xu Y, Ge JB, Shimizu Y, Bache RJ, Chen Y. CD28/B7 Deficiency Attenuates Systolic Overload-Induced Congestive Heart Failure, Myocardial and Pulmonary Inflammation, and Activated T Cell Accumulation in the Heart and Lungs. Hypertension 2016; 68:688-96. [PMID: 27432861 DOI: 10.1161/hypertensionaha.116.07579] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 06/09/2016] [Indexed: 11/16/2022]
Abstract
The inflammatory response regulates congestive heart failure (CHF) development. T cell activation plays an important role in tissue inflammation. We postulate that CD28 or B7 deficiency inhibits T cell activation and attenuates CHF development by reducing systemic, cardiac, and pulmonary inflammation. We demonstrated that chronic pressure overload-induced end-stage CHF in mice is characterized by profound accumulation of activated effector T cells (CD3(+)CD44(high) cells) in the lungs and a mild but significant increase of these cells in the heart. In knockout mice lacking either CD28 or B7, there was a dramatic reduction in the accumulation of activated effector T cells in both hearts and lungs of mice under control conditions and after transverse aortic constriction. CD28 or B7 knockout significantly attenuated transverse aortic constriction-induced CHF development, as indicated by less increase of heart and lung weight and less reduction of left ventricle contractility. CD28 or B7 knockout also significantly reduced transverse aortic constriction-induced CD45(+) leukocyte, T cell, and macrophage infiltration in hearts and lungs, lowered proinflammatory cytokine expression (such as tumor necrosis factor-α and interleukin-1β) in lungs. Furthermore, CD28/B7 blockade by CTLA4-Ig treatment (250 μg/mouse every 3 days) attenuated transverse aortic constriction-induced T cell activation, left ventricle hypertrophy, and left ventricle dysfunction. Our data indicate that CD28/B7 deficiency inhibits activated effector T cell accumulation, reduces myocardial and pulmonary inflammation, and attenuates the development of CHF. Our findings suggest that strategies targeting T cell activation may be useful in treating CHF.
Collapse
Affiliation(s)
- Huan Wang
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Dongmin Kwak
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - John Fassett
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Lei Hou
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Xin Xu
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Brandon J Burbach
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Thenappan Thenappan
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Yawei Xu
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Jun-Bo Ge
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Yoji Shimizu
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Robert J Bache
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.)
| | - Yingjie Chen
- From the Cardiovascular Division and Lillehei Heart Institute (H.W., D.K., X.X., T.T., R.J.B., Y.C.) and Department of Laboratory Medicine and Pathology, Center for Immunology, Department of Medicine, Masonic Cancer Center (B.J.B., Y.S.), University of Minnesota Medical School, Minneapolis; Department of Pharmacology and Toxicology, University of Graz, Austria (J.F.); and Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, China (L.H., Y.X., J.-b.G.).
| |
Collapse
|
191
|
Abstract
As a greater proportion of patients survive their initial cardiac insult, medical systems worldwide are being faced with an ever-growing need to understand the mechanisms behind the pathogenesis of chronic heart failure (HF). There is a wealth of information about the role of inflammatory cells and pathways during acute injury and the reparative processes that are subsequently activated. We discuss the different causes that lead to chronic HF development and how the sum of initial inflammatory and reparative responses only sets the trajectory for disease progression. Unfortunately, comparatively little is known about the contribution of the immune system once the trajectory has been set, and chronic HF has been established—which clinically represents the majority of patients. It is known that chronic HF is associated with circulating inflammatory cytokines that can predict clinical outcomes, yet the causative role inflammation plays in disease progression is not well defined, and the majority of clinical trials that target aspects of inflammation in patients with chronic HF have largely been negative. This review will present what is currently known about inflammation in chronic HF in both humans and animal models as a means to highlight the gap in our knowledge base that requires further examination.
Collapse
Affiliation(s)
- Sarah A. Dick
- From the Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada (S.A.D, S.E.); University of Toronto, Toronto, Ontario, Canada (S.E); Peter Munk Cardiac Centre, Toronto, Ontario, Canada (S.A.D, S.E.); and Toronto General Hospital Research Institute, Toronto, Ontario, Canada (S.A.D, S.E.)
| | - Slava Epelman
- From the Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada (S.A.D, S.E.); University of Toronto, Toronto, Ontario, Canada (S.E); Peter Munk Cardiac Centre, Toronto, Ontario, Canada (S.A.D, S.E.); and Toronto General Hospital Research Institute, Toronto, Ontario, Canada (S.A.D, S.E.)
| |
Collapse
|
192
|
Wang H, Hou L, Kwak D, Fassett J, Xu X, Chen A, Chen W, Blazar BR, Xu Y, Hall JL, Ge JB, Bache RJ, Chen Y. Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression. Hypertension 2016; 68:114-22. [PMID: 27160197 DOI: 10.1161/hypertensionaha.116.07084] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Accepted: 04/01/2016] [Indexed: 12/20/2022]
Abstract
Congestive heart failure (CHF) is associated with an increase of leukocyte infiltration, proinflammatory cytokines, and fibrosis in the heart and lung. Regulatory T cells (Tregs, CD4(+)CD25(+)FoxP3(+)) suppress inflammatory responses in various clinical conditions. We postulated that expansion of Tregs attenuates CHF progression by reducing cardiac and lung inflammation. We investigated the effects of interleukin-2 (IL-2) plus IL-2 monoclonal antibody clone JES6-1 complexes (IL2/JES6-1) on induction of Tregs, transverse aortic constriction-induced cardiac and lung inflammation, and CHF progression in mice. We demonstrated that end-stage CHF caused a massive increase of lung macrophages and T cells, as well as relatively mild left ventricular (LV) leukocyte infiltration. Administration of IL2/JES6-1 caused an ≈6-fold increase of Tregs within CD4(+) T cells in the spleen, lung, and heart of mice. IL2/JES6-1 treatment of mice with existing transverse aortic constriction-induced LV failure markedly reduced lung and right ventricular weight and improved LV ejection fraction and LV end-diastolic pressure. Mechanistically, IL2/JES6-1 treatment significantly increased Tregs; suppressed CD4(+) T-cell accumulation; dramatically attenuated leukocyte infiltration, including decreasing CD45(+) cells, macrophages, CD8(+) T cells, and effector memory CD8(+); and reduced proinflammatory cytokine expressions and fibrosis in the lung of mice. Furthermore, IL2/JES6-1 administered before transverse aortic constriction attenuated the development of LV hypertrophy and dysfunction in mice. Our data indicate that increasing Tregs through administration of IL2/JES6-1 effectively attenuates pulmonary inflammation, right ventricular hypertrophy, and further LV dysfunction in mice with existing LV failure, suggesting that strategies to properly expand Tregs may be useful in reducing CHF progression.
Collapse
Affiliation(s)
- Huan Wang
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Lei Hou
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Dongmin Kwak
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - John Fassett
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Xin Xu
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Angela Chen
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Wei Chen
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Bruce R Blazar
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Yawei Xu
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Jennifer L Hall
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Jun-Bo Ge
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Robert J Bache
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| | - Yingjie Chen
- From the Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.W., D.K., J.F., X.X., A.C., J.L.H., R.J.B., Y.C.); Department of Cardiology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (L.H., Y.X., J.-b.G.); and Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis (W.C., B.R.B.)
| |
Collapse
|
193
|
Youn JC, Lee HS, Choi SW, Han SW, Ryu KH, Shin EC, Kang SM. Post-Exercise Heart Rate Recovery Independently Predicts Clinical Outcome in Patients with Acute Decompensated Heart Failure. PLoS One 2016; 11:e0154534. [PMID: 27135610 PMCID: PMC4852907 DOI: 10.1371/journal.pone.0154534] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Accepted: 04/14/2016] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Post-exercise heart rate recovery (HRR) is an index of parasympathetic function associated with clinical outcome in patients with chronic heart failure. However, its relationship with the pro-inflammatory response and prognostic value in consecutive patients with acute decompensated heart failure (ADHF) has not been investigated. METHODS We measured HRR and pro-inflammatory markers in 107 prospectively and consecutively enrolled, recovered ADHF patients (71 male, 59 ± 15 years, mean ejection fraction 28.9 ± 14.2%) during the pre-discharge period. The primary endpoint included cardiovascular (CV) events defined as CV mortality, cardiac transplantation, or rehospitalization due to HF aggravation. RESULTS The CV events occurred in 30 (28.0%) patients (5 cardiovascular deaths and 7 cardiac transplantations) during the follow-up period (median 214 days, 11-812 days). When the patients with ADHF were grouped by HRR according to the Contal and O'Quigley's method, low HRR was shown to be associated with significantly higher levels of serum monokine-induced by gamma interferon (MIG) and poor clinical outcome. Multivariate Cox regression analysis revealed that low HRR was an independent predictor of CV events in both enter method and stepwise method. The addition of HRR to a model significantly increased predictability for CV events across the entire follow-up period. CONCLUSION Impaired post-exercise HRR is associated with a pro-inflammatory response and independently predicts clinical outcome in patients with ADHF. These findings may explain the relationship between autonomic dysfunction and clinical outcome in terms of the inflammatory response in these patients.
Collapse
Affiliation(s)
- Jong-Chan Youn
- Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Hye Sun Lee
- Department of Biostatistics, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Suk-Won Choi
- Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea
| | - Seong-Woo Han
- Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea
| | - Kyu-Hyung Ryu
- Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea
| | - Eui-Cheol Shin
- Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea
| | - Seok-Min Kang
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
- * E-mail:
| |
Collapse
|
194
|
Smith JG, Felix JF, Morrison AC, Kalogeropoulos A, Trompet S, Wilk JB, Gidlöf O, Wang X, Morley M, Mendelson M, Joehanes R, Ligthart S, Shan X, Bis JC, Wang YA, Sjögren M, Ngwa J, Brandimarto J, Stott DJ, Aguilar D, Rice KM, Sesso HD, Demissie S, Buckley BM, Taylor KD, Ford I, Yao C, Liu C, Sotoodehnia N, van der Harst P, Stricker BHC, Kritchevsky SB, Liu Y, Gaziano JM, Hofman A, Moravec CS, Uitterlinden AG, Kellis M, van Meurs JB, Margulies KB, Dehghan A, Levy D, Olde B, Psaty BM, Cupples LA, Jukema JW, Djousse L, Franco OH, Boerwinkle E, Boyer LA, Newton-Cheh C, Butler J, Vasan RS, Cappola TP, Smith NL. Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure. PLoS Genet 2016; 12:e1006034. [PMID: 27149122 PMCID: PMC4858216 DOI: 10.1371/journal.pgen.1006034] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Accepted: 04/18/2016] [Indexed: 11/22/2022] Open
Abstract
Failure of the human heart to maintain sufficient output of blood for the demands of the body, heart failure, is a common condition with high mortality even with modern therapeutic alternatives. To identify molecular determinants of mortality in patients with new-onset heart failure, we performed a meta-analysis of genome-wide association studies and follow-up genotyping in independent populations. We identified and replicated an association for a genetic variant on chromosome 5q22 with 36% increased risk of death in subjects with heart failure (rs9885413, P = 2.7x10-9). We provide evidence from reporter gene assays, computational predictions and epigenomic marks that this polymorphism increases activity of an enhancer region active in multiple human tissues. The polymorphism was further reproducibly associated with a DNA methylation signature in whole blood (P = 4.5x10-40) that also associated with allergic sensitization and expression in blood of the cytokine TSLP (P = 1.1x10-4). Knockdown of the transcription factor predicted to bind the enhancer region (NHLH1) in a human cell line (HEK293) expressing NHLH1 resulted in lower TSLP expression. In addition, we observed evidence of recent positive selection acting on the risk allele in populations of African descent. Our findings provide novel genetic leads to factors that influence mortality in patients with heart failure.
Collapse
Affiliation(s)
- J. Gustav Smith
- Department of Cardiology, Department of Clinical Sciences, Lund University, Lund, Sweden
- Department of Heart Failure and Valvular Disease, Skåne University Hospital, Lund, Sweden
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America
- Center for Human Genetic Research and Cardiovascular Research Center, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Janine F. Felix
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- Netherlands Consortium for Healthy Aging (NGI-NCHA), The Netherlands Genomics Initiative, Leiden, the Netherlands
| | - Alanna C. Morrison
- Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, United States of America
| | - Andreas Kalogeropoulos
- Emory Clinical Cardiovascular Research Institute, Emory University, Atlanta, Georgia, United States of America
| | - Stella Trompet
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
- Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands
| | - Jemma B. Wilk
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Olof Gidlöf
- Department of Cardiology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Xinchen Wang
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America
- Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
| | - Michael Morley
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Michael Mendelson
- The Framingham Heart Study, Framingham, Massachusetts, United States of America
- The Population Sciences Branch, National Heart, Lund and Blood Institute, Bethesda, Maryland, United States of America
- Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, United States of America
| | - Roby Joehanes
- The Framingham Heart Study, Framingham, Massachusetts, United States of America
- The Population Sciences Branch, National Heart, Lund and Blood Institute, Bethesda, Maryland, United States of America
| | - Symen Ligthart
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Xiaoyin Shan
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Joshua C. Bis
- Department of Epidemiology, University of Washington, Seattle, Washington, United States of America
| | - Ying A. Wang
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
| | - Marketa Sjögren
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Julius Ngwa
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America
| | - Jeffrey Brandimarto
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - David J. Stott
- Academic Section of Geriatric Medicine, Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom
| | - David Aguilar
- Baylor College of Medicine, Houston, Texas, United States of America
| | - Kenneth M. Rice
- Department of Biostatistics, University of Washington, Seattle, Washington, United States of America
| | - Howard D. Sesso
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Serkalem Demissie
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America
| | - Brendan M. Buckley
- Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland
| | - Kent D. Taylor
- Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute and Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, California, United States of America
| | - Ian Ford
- Robertson Center for Biostatistics, University of Glasgow, Glasgow, United Kingdom
| | - Chen Yao
- The Framingham Heart Study, Framingham, Massachusetts, United States of America
- The Population Sciences Branch, National Heart, Lund and Blood Institute, Bethesda, Maryland, United States of America
| | - Chunyu Liu
- The Framingham Heart Study, Framingham, Massachusetts, United States of America
- The Population Sciences Branch, National Heart, Lund and Blood Institute, Bethesda, Maryland, United States of America
| | | | | | | | | | - Nona Sotoodehnia
- Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Pim van der Harst
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Bruno H. Ch. Stricker
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- Inspectorate for Health Care, The Hague, the Netherlands
- Department of Medical Informatics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Stephen B. Kritchevsky
- Department of Internal Medicine, Section on Geronotology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America
| | - Yongmei Liu
- Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States of America
| | - J. Michael Gaziano
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Albert Hofman
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Christine S. Moravec
- Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America
| | - André G. Uitterlinden
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- Netherlands Consortium for Healthy Aging (NGI-NCHA), The Netherlands Genomics Initiative, Leiden, the Netherlands
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Manolis Kellis
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America
- Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
| | - Joyce B. van Meurs
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Kenneth B. Margulies
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Abbas Dehghan
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Daniel Levy
- The Framingham Heart Study, Framingham, Massachusetts, United States of America
- The Population Sciences Branch, National Heart, Lund and Blood Institute, Bethesda, Maryland, United States of America
| | - Björn Olde
- Department of Cardiology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Bruce M. Psaty
- Department of Epidemiology, University of Washington, Seattle, Washington, United States of America
- Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, United States of America
- Department of Health Services, University of Washington, Seattle, Washington, United States of America
- Group Health Research Institute, Group Health Cooperative, Seattle, Washington, United States of America
| | - L. Adrienne Cupples
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America
| | - J. Wouter Jukema
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
- Durrer Center for Cardiogenetic Research, Amsterdam, the Netherlands
- Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands
| | - Luc Djousse
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Oscar H. Franco
- Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- Netherlands Consortium for Healthy Aging (NGI-NCHA), The Netherlands Genomics Initiative, Leiden, the Netherlands
| | - Eric Boerwinkle
- Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, United States of America
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, United States of America
| | - Laurie A. Boyer
- Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
| | - Christopher Newton-Cheh
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America
- Center for Human Genetic Research and Cardiovascular Research Center, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America
| | - Javed Butler
- Emory Clinical Cardiovascular Research Institute, Emory University, Atlanta, Georgia, United States of America
| | - Ramachandran S. Vasan
- Departments of Medicine and Preventive Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | - Thomas P. Cappola
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Nicholas L. Smith
- Department of Epidemiology, University of Washington, Seattle, Washington, United States of America
- Department of Health Services, University of Washington, Seattle, Washington, United States of America
- Seattle Epidemiologic Research and Information Center, Department of Veteran Affairs Office of Research and Development, Seattle, Washington, United States of America
| |
Collapse
|
195
|
Suzuki K, Satoh K, Ikeda S, Sunamura S, Otsuki T, Satoh T, Kikuchi N, Omura J, Kurosawa R, Nogi M, Numano K, Sugimura K, Aoki T, Tatebe S, Miyata S, Mukherjee R, Spinale FG, Kadomatsu K, Shimokawa H. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. Arterioscler Thromb Vasc Biol 2016; 36:636-46. [DOI: 10.1161/atvbaha.115.306686] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Accepted: 02/16/2016] [Indexed: 01/08/2023]
Affiliation(s)
- Kota Suzuki
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Kimio Satoh
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Shohei Ikeda
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Shinichiro Sunamura
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Tomohiro Otsuki
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Taijyu Satoh
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Nobuhiro Kikuchi
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Junichi Omura
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Ryo Kurosawa
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Masamichi Nogi
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Kazuhiko Numano
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Koichiro Sugimura
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Tatsuo Aoki
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Shunsuke Tatebe
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Satoshi Miyata
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Rupak Mukherjee
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Francis G. Spinale
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Kenji Kadomatsu
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| | - Hiroaki Shimokawa
- From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., K.S., S.I., S.S., T.O., T.S., N.K., J.O., R.K., M.N., K.N., K.S., T.A., S.T., H.S.); Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston (R.M.); Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia (F.G.S.); and Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K.)
| |
Collapse
|
196
|
Salvador AM, Nevers T, Velázquez F, Aronovitz M, Wang B, Abadía Molina A, Jaffe IZ, Karas RH, Blanton RM, Alcaide P. Intercellular Adhesion Molecule 1 Regulates Left Ventricular Leukocyte Infiltration, Cardiac Remodeling, and Function in Pressure Overload-Induced Heart Failure. J Am Heart Assoc 2016; 5:e003126. [PMID: 27068635 PMCID: PMC4943280 DOI: 10.1161/jaha.115.003126] [Citation(s) in RCA: 95] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Background Left ventricular dysfunction and heart failure are strongly associated in humans with increased circulating levels of proinflammatory cytokines, T cells, and soluble intercellular cell adhesion molecule 1 (ICAM1). In mice, infiltration of T cells into the left ventricle contributes to pathological cardiac remodeling, but the mechanisms regulating their recruitment to the heart are unclear. We hypothesized that ICAM1 regulates cardiac inflammation and pathological cardiac remodeling by mediating left ventricular T‐cell recruitment and thus contributing to cardiac dysfunction and heart failure. Methods and Results In a mouse model of pressure overload–induced heart failure, intramyocardial endothelial ICAM1 increased within 48 hours in response to thoracic aortic constriction and remained upregulated as heart failure progressed. ICAM1‐deficient mice had decreased T‐cell and proinflammatory monocyte infiltration in the left ventricle in response to thoracic aortic constriction, despite having numbers of circulating T cells and activated T cells in the heart‐draining lymph nodes that were similar to those of wild‐type mice. ICAM1‐deficient mice did not develop cardiac fibrosis or systolic and diastolic dysfunction in response to thoracic aortic constriction. Exploration of the mechanisms regulating ICAM1 expression revealed that endothelial ICAM1 upregulation and T‐cell infiltration were not mediated by endothelial mineralocorticoid receptor signaling, as demonstrated in thoracic aortic constriction studies in mice with endothelial mineralocorticoid receptor deficiency, but rather were induced by the cardiac cytokines interleukin 1β and 6. Conclusions ICAM1 regulates pathological cardiac remodeling by mediating proinflammatory leukocyte infiltration in the left ventricle and cardiac fibrosis and dysfunction and thus represents a novel target for treatment of heart failure.
Collapse
Affiliation(s)
- Ane M Salvador
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA Centro de Investigaciόn Biomédica, Universidad de Granada, Spain
| | - Tania Nevers
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA
| | - Francisco Velázquez
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA Sackler School for Graduate studies, Tufts University School of Medicine, Boston, MA
| | - Mark Aronovitz
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA
| | - Bonnie Wang
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA
| | | | - Iris Z Jaffe
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA Sackler School for Graduate studies, Tufts University School of Medicine, Boston, MA
| | - Richard H Karas
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA Sackler School for Graduate studies, Tufts University School of Medicine, Boston, MA
| | - Robert M Blanton
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA
| | - Pilar Alcaide
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA Sackler School for Graduate studies, Tufts University School of Medicine, Boston, MA
| |
Collapse
|
197
|
Ramos G, Hofmann U, Frantz S. Myocardial fibrosis seen through the lenses of T-cell biology. J Mol Cell Cardiol 2016; 92:41-5. [PMID: 26804387 DOI: 10.1016/j.yjmcc.2016.01.018] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Revised: 01/20/2016] [Accepted: 01/20/2016] [Indexed: 01/07/2023]
Abstract
Lymphocytes came recently into focus as modulators of non-infectious myocardial diseases. Several lines of experimental evidence now indicate that CD4(+) T-cells can influence the healing and scarring processes that follow a myocardial infarction episode. Furthermore, such heart-directed T-cell activity has also been implicated in the pathogenesis cardiac remodeling that develops in response to chronic pressure-overload conditions. Mechanistically, different T-cell subsets can secrete several mediators and growth factors that influence the myocardial molecular milieu and directly interfere with the macrophages' and fibroblasts' activity. Therefore, the present review summarizes the current experimental evidence on the role of T-cells in myocardial scar formation after infarction and myocardial fibrosis as central mechanism of ventricular remodeling.
Collapse
Affiliation(s)
- Gustavo Ramos
- University Clinic Halle, Department of Internal Medicine III, D-06120 Halle, Germany
| | - Ulrich Hofmann
- University Clinic Halle, Department of Internal Medicine III, D-06120 Halle, Germany; Comprehensive Heart Failure Center, Würzburg, D-97078 Würzburg, Germany
| | - Stefan Frantz
- University Clinic Halle, Department of Internal Medicine III, D-06120 Halle, Germany.
| |
Collapse
|
198
|
Mialet-Perez J, Douin-Echinard V, Cussac D, Bril A, Parini A. [Ageing: a matter of heart?]. Med Sci (Paris) 2015; 31:1006-13. [PMID: 26576608 DOI: 10.1051/medsci/20153111015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Ageing is considered as a major risk factor for the development of chronic diseases. Among these, heart failure seems to be particularly important for both triggering and accelerating pathological ageing. In the present review, we give a general overview of the most relevant results concerning the mechanism of normal and premature senescence of cardiomyocytes and cardiac stromal cells. In particular, we will address the role of telomere dysfunction, DNA damage response, impairment of mitochondrial function, miRNAs and secretome of senescent cells in cardiac ageing and failure.
Collapse
Affiliation(s)
- Jeanne Mialet-Perez
- Inserm, UMR1048, institut des maladies métaboliques et cardiovasculaires, 1, avenue Jean Poulhès, BP 84225, 31432 Toulouse cedex 4, France - Université Paul Sabatier, Toulouse, France
| | - Victorine Douin-Echinard
- Inserm, UMR1048, institut des maladies métaboliques et cardiovasculaires, 1, avenue Jean Poulhès, BP 84225, 31432 Toulouse cedex 4, France - Université Paul Sabatier, Toulouse, France
| | - Daniel Cussac
- Inserm, UMR1048, institut des maladies métaboliques et cardiovasculaires, 1, avenue Jean Poulhès, BP 84225, 31432 Toulouse cedex 4, France - Université Paul Sabatier, Toulouse, France
| | - Antoine Bril
- Institut de recherches internationales Servier, Suresnes, France
| | - Angelo Parini
- Inserm, UMR1048, institut des maladies métaboliques et cardiovasculaires, 1, avenue Jean Poulhès, BP 84225, 31432 Toulouse cedex 4, France - Université Paul Sabatier, Toulouse, France
| |
Collapse
|
199
|
Abstract
Cardiac hypertrophy is characterized by complex multicellular alterations, such as cardiomyocyte growth, angiogenesis, fibrosis, and inflammation. The heart consists of myocytes and nonmyocytes, such as fibroblasts, vascular cells, and blood cells, and these cells communicate with each other directly or indirectly via a variety of autocrine or paracrine mediators. Accumulating evidence has suggested that nonmyocytes actively participate in the development of cardiac hypertrophy. In this review, recent progress in our understanding of the importance of nonmyocytes as a hub for induction of cardiac hypertrophy is summarized with an emphasis of the contribution of noncontact communication mediated by diffusible factors between cardiomyocytes and nonmyocytes in the heart.
Collapse
Affiliation(s)
- Takehiro Kamo
- From the Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (T.K., H.A., I.K.); and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Chiyoda-ku, Tokyo, Japan (H.A., I.K.)
| | - Hiroshi Akazawa
- From the Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (T.K., H.A., I.K.); and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Chiyoda-ku, Tokyo, Japan (H.A., I.K.)
| | - Issei Komuro
- From the Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (T.K., H.A., I.K.); and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Chiyoda-ku, Tokyo, Japan (H.A., I.K.)
| |
Collapse
|
200
|
Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velázquez F, Aronovitz M, Kapur NK, Karas RH, Blanton RM, Alcaide P. Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure. Circ Heart Fail 2015; 8:776-87. [PMID: 26022677 DOI: 10.1161/circheartfailure.115.002225] [Citation(s) in RCA: 187] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Accepted: 05/15/2015] [Indexed: 01/09/2023]
Abstract
BACKGROUND Despite the emerging association between heart failure (HF) and inflammation, the role of T cells, major players in chronic inflammation, has only recently begun to be explored. Whether T-cell recruitment to the left ventricle (LV) participates in the development of HF requires further investigation to identify novel mechanisms that may serve for the design of alternative therapeutic interventions. METHODS AND RESULTS Real-time videomicroscopy of T cells from nonischemic HF patients or from mice with HF induced by transverse aortic constriction revealed enhanced adhesion to activated vascular endothelial cells under flow conditions in vitro compared with T cells from healthy subjects or sham mice. T cells in the mediastinal lymph nodes and the intramyocardial endothelium were both activated in response to transverse aortic constriction and the kinetics of LV T-cell infiltration was directly associated with the development of systolic dysfunction. In response to transverse aortic constriction, T cell-deficient mice (T-cell receptor, TCRα(-/-)) had preserved LV systolic and diastolic function, reduced LV fibrosis, hypertrophy and inflammation, and improved survival compared with wild-type mice. Furthermore, T-cell depletion in wild-type mice after transverse aortic constriction prevented HF. CONCLUSIONS T cells are major contributors to nonischemic HF. Their activation combined with the activation of the LV endothelium results in LV T-cell infiltration negatively contributing to HF progression through mechanisms involving cytokine release and induction of cardiac fibrosis and hypertrophy. Reduction of T-cell infiltration is thus identified as a novel translational target in HF.
Collapse
Affiliation(s)
- Tania Nevers
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Ane M Salvador
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Anna Grodecki-Pena
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Andrew Knapp
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Francisco Velázquez
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Mark Aronovitz
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Navin K Kapur
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Richard H Karas
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Robert M Blanton
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.)
| | - Pilar Alcaide
- From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
| |
Collapse
|